// ============================================================
// TERRAIN — Procedure & Device Market Database
// lib/data/procedure-map.ts
//
// The device/diagnostics equivalent of indication-map.ts
// 63 procedures across 20 device categories
//
// Sources: CMS claims data, AHA Annual Survey, Definitive Healthcare,
// MedPAC data books, published surgical society statistics,
// device company investor presentations, specialty society registries
// ============================================================

import type { ProcedureData } from '@/types/devices-diagnostics';

export const PROCEDURE_DATA: ProcedureData[] = [

  // ──────────────────────────────────────────────────────────
  // CARDIOVASCULAR DEVICES
  // ──────────────────────────────────────────────────────────

  {
    name: 'Transcatheter Aortic Valve Replacement',
    synonyms: ['TAVR', 'TAVI', 'transcatheter aortic valve implantation', 'aortic valve replacement minimally invasive'],
    cpt_codes: ['33361', '33362', '33363', '33364', '33365', '33366'],
    drg_codes: ['266', '267'],
    device_category: 'cardiovascular',
    us_annual_procedures: 110000,
    us_procedure_growth_rate: 8.5,
    procedure_setting: ['hospital_inpatient', 'hospital_outpatient'],
    eligible_sites: { hospitals: 850, ascs: 0, clinics: 0 },
    performing_specialty: ['Interventional Cardiology', 'Cardiac Surgery'],
    adoption_barrier: 'moderate',
    procedure_source: 'TVT Registry / STS-ACC 2024; CMS Medicare data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 32000,
      medicare_physician_rate: 1500,
      private_payer_coverage: 'Commercial coverage established. Prior authorization common. Evidence-based criteria (STS/ACC appropriate use).',
    },
    major_device_competitors: ['Edwards Sapien 3 (Edwards)', 'Evolut (Medtronic)', 'Acurate (Boston Scientific)', 'Myval (Meril Life)'],
    market_leader: 'Edwards Lifesciences (Sapien platform)',
    market_leader_share_pct: 48,
    current_standard_of_care: 'SAVR (surgical AVR) for younger, low-risk patients; TAVR has become standard for most patients, including low-risk since 2019',
    cagr_5yr: 8.5,
    growth_driver: 'Expanding to younger, lower-risk patients; borderline indication patients; aortic regurgitation indication',
  },

  {
    name: 'Cardiac Ablation for Atrial Fibrillation',
    synonyms: ['AF ablation', 'AFib ablation', 'pulmonary vein isolation', 'PVI', 'catheter ablation afib', 'pulsed field ablation'],
    cpt_codes: ['93656', '93657', '93750'],
    drg_codes: ['247', '248'],
    device_category: 'cardiovascular',
    us_annual_procedures: 250000,
    us_procedure_growth_rate: 12.0,
    procedure_setting: ['hospital_outpatient', 'hospital_inpatient'],
    eligible_sites: { hospitals: 1200, ascs: 50 },
    performing_specialty: ['Cardiac Electrophysiology'],
    adoption_barrier: 'moderate',
    procedure_source: 'AHA Heart Disease Statistics 2024; EP Lab Digest',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 18000,
      medicare_physician_rate: 3200,
      private_payer_coverage: 'Covered after antiarrhythmic drug failure. Pulsed field ablation gaining coverage.',
    },
    major_device_competitors: [
      'Thermocool SmartTouch (Biosense Webster/J&J)',
      'Arctic Front Advance (Medtronic)',
      'Farapulse (Boston Scientific)',
      'Heliostar (Medtronic, balloon)',
    ],
    market_leader: 'Biosense Webster (J&J MedTech)',
    market_leader_share_pct: 42,
    current_standard_of_care: 'Radiofrequency ablation (RF) dominant; cryoablation ~25% share; pulsed field ablation (PFA) rapidly gaining post-FDA clearance',
    cagr_5yr: 12.0,
    growth_driver: 'PFA technology driving procedure growth, earlier treatment, less repeat procedures, expansion to persistent AFib',
  },

  {
    name: 'Coronary Stent Implantation',
    synonyms: ['PCI', 'percutaneous coronary intervention', 'coronary stenting', 'drug-eluting stent', 'DES implantation'],
    cpt_codes: ['92928', '92929', '92933', '92934'],
    drg_codes: ['247', '248', '251', '252'],
    device_category: 'cardiovascular',
    us_annual_procedures: 650000,
    us_procedure_growth_rate: 1.5,
    procedure_setting: ['hospital_inpatient', 'hospital_outpatient'],
    eligible_sites: { hospitals: 1800 },
    performing_specialty: ['Interventional Cardiology'],
    adoption_barrier: 'low',
    procedure_source: 'NCDR CathPCI Registry 2024; AHA Statistics',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 12000,
      medicare_physician_rate: 800,
      private_payer_coverage: 'Universal coverage; prior auth for elective procedures',
    },
    major_device_competitors: [
      'Xience (Abbott)',
      'Synergy (Boston Scientific)',
      'Resolute Onyx (Medtronic)',
      'Ultimaster (Terumo)',
      'Orsiro (Biotronik)',
    ],
    market_leader: 'Abbott (Xience platform)',
    market_leader_share_pct: 35,
    current_standard_of_care: 'Drug-eluting stents (DES) gold standard. Bioresorbable scaffolds had setbacks; thin-strut DES dominant.',
    cagr_5yr: 2.0,
    growth_driver: 'Modest growth; mature market. Innovation in thin-strut design, polymer-free platforms, and chronic total occlusion (CTO) stenting',
  },

  // ──────────────────────────────────────────────────────────
  // ORTHOPEDIC DEVICES
  // ──────────────────────────────────────────────────────────

  {
    name: 'Total Knee Replacement',
    synonyms: ['TKA', 'total knee arthroplasty', 'knee replacement', 'TKR', 'primary knee replacement'],
    cpt_codes: ['27447'],
    drg_codes: ['470', '469'],
    device_category: 'orthopedic',
    us_annual_procedures: 1030000,
    us_procedure_growth_rate: 4.2,
    procedure_setting: ['hospital_inpatient', 'hospital_outpatient', 'asc'],
    eligible_sites: { hospitals: 3200, ascs: 1800 },
    performing_specialty: ['Orthopedic Surgery'],
    adoption_barrier: 'low',
    procedure_source: 'AJRR (American Joint Replacement Registry) 2024; CMS MEDPAR',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 12000,
      medicare_physician_rate: 1400,
      private_payer_coverage: 'Universal commercial coverage. ASC-setting coverage expanding post-2020 CMS rule change.',
    },
    major_device_competitors: [
      'Triathlon (Stryker)',
      'Attune (DePuy Synthes/J&J)',
      'Vanguard (Zimmer Biomet)',
      'Journey II (Smith+Nephew)',
      'Persona (Zimmer Biomet)',
    ],
    market_leader: 'Zimmer Biomet + Stryker (~60% combined)',
    market_leader_share_pct: 30,
    current_standard_of_care: 'Cemented TKA with fixed-bearing or mobile-bearing implants. Robotic-assisted growing rapidly (~25% of procedures).',
    cagr_5yr: 4.2,
    growth_driver: 'Aging population, obesity epidemic, ASC shift, robotic surgery adoption (Mako, Rosa, CORI)',
  },

  {
    name: 'Total Hip Replacement',
    synonyms: ['THA', 'total hip arthroplasty', 'hip replacement', 'THR', 'primary hip replacement'],
    cpt_codes: ['27130'],
    drg_codes: ['470', '469'],
    device_category: 'orthopedic',
    us_annual_procedures: 750000,
    us_procedure_growth_rate: 3.8,
    procedure_setting: ['hospital_inpatient', 'hospital_outpatient', 'asc'],
    eligible_sites: { hospitals: 3000, ascs: 1200 },
    performing_specialty: ['Orthopedic Surgery'],
    adoption_barrier: 'low',
    procedure_source: 'AJRR 2024; CMS MEDPAR data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 11500,
      medicare_physician_rate: 1300,
      private_payer_coverage: 'Universal commercial coverage.',
    },
    major_device_competitors: [
      'Trident/Secur-Fit (Stryker)',
      'Pinnacle (DePuy Synthes)',
      'Continuum (Zimmer Biomet)',
      'Redapt (Smith+Nephew)',
    ],
    market_leader: 'Stryker',
    market_leader_share_pct: 28,
    current_standard_of_care: 'Cementless fixation dominant. Highly cross-linked polyethylene liner. Ceramic femoral head growing.',
    cagr_5yr: 3.8,
    growth_driver: 'Aging demographics, obesity, ASC migration, improved implant longevity enabling younger patients',
  },

  {
    name: 'Spinal Fusion',
    synonyms: ['vertebral fusion', 'ACDF', 'TLIF', 'PLIF', 'lumbar fusion', 'cervical fusion', 'spine surgery'],
    cpt_codes: ['22612', '22630', '22551', '22552', '22845', '22846'],
    drg_codes: ['459', '460', '473', '474'],
    device_category: 'orthopedic',
    us_annual_procedures: 600000,
    us_procedure_growth_rate: 2.5,
    procedure_setting: ['hospital_inpatient', 'hospital_outpatient', 'asc'],
    eligible_sites: { hospitals: 3500, ascs: 2000 },
    performing_specialty: ['Orthopedic Surgery', 'Neurosurgery'],
    adoption_barrier: 'moderate',
    procedure_source: 'NIS/HCUP 2024; North American Spine Society (NASS)',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 18000,
      medicare_physician_rate: 1800,
      private_payer_coverage: 'Coverage with clinical criteria; conservative treatment failure required. Vary by level and approach.',
    },
    major_device_competitors: [
      'Medtronic (largest share)',
      'DePuy Synthes Spine (J&J)',
      'Stryker Spine (K2M)',
      'Globus Medical',
      'NuVasive (Globus)',
      'Alphatec',
    ],
    market_leader: 'Medtronic Spine',
    market_leader_share_pct: 25,
    current_standard_of_care: 'Pedicle screw fixation + interbody cage. ACDF for cervical. LLIF/TLIF for lumbar. Robotic guidance growing.',
    cagr_5yr: 2.5,
    growth_driver: 'Aging population, minimally invasive approaches (MIS), robotic-assisted spine surgery, expandable cages',
  },

  // ──────────────────────────────────────────────────────────
  // DIABETES / METABOLIC
  // ──────────────────────────────────────────────────────────

  {
    name: 'Continuous Glucose Monitor (CGM)',
    synonyms: ['CGM', 'continuous glucose monitoring', 'real-time CGM', 'flash glucose monitoring', 'FGM'],
    cpt_codes: ['95250', '95251', '99453', '99454'],
    drg_codes: [],
    device_category: 'diabetes_metabolic',
    us_annual_procedures: 4200000,  // Active CGM users (patient-years)
    us_procedure_growth_rate: 18.0,
    procedure_setting: ['home', 'office'],
    eligible_sites: { hospitals: 0, ascs: 0, clinics: 8000 },
    performing_specialty: ['Endocrinology', 'Primary Care', 'Diabetes Education'],
    adoption_barrier: 'low',
    procedure_source: 'Dexcom / Abbott investor presentations; ADA 2024',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_physician_rate: 120,    // Monthly (supply cost covered by durable medical equipment benefit)
      private_payer_coverage: 'Medicare covers for insulin-treated diabetes. Commercial coverage broad for T1D; expanding rapidly for T2D. 2023 ADA guidance supports T2D CGM.',
    },
    major_device_competitors: [
      'Dexcom G7',
      'FreeStyle Libre 3 (Abbott)',
      'Eversense E3 (Senseonics, 6-month implantable)',
      'Guardian 4 (Medtronic)',
    ],
    market_leader: 'Dexcom + Abbott (combined ~85% market)',
    market_leader_share_pct: 42,
    current_standard_of_care: 'Real-time CGM replacing fingerstick testing for insulin-treated diabetes. Patch design (14-day wear) dominant.',
    cagr_5yr: 18.0,
    growth_driver: 'Type 2 diabetes expansion (massive untreated population), closed-loop insulin delivery systems, remote patient monitoring reimbursement',
  },

  {
    name: 'Insulin Pump Therapy',
    synonyms: ['insulin pump', 'CSII', 'continuous subcutaneous insulin infusion', 'AID system', 'automated insulin delivery', 'closed loop'],
    cpt_codes: ['E0784'],
    drg_codes: [],
    device_category: 'diabetes_metabolic',
    us_annual_procedures: 600000,  // Active pump users
    us_procedure_growth_rate: 8.0,
    procedure_setting: ['home', 'office'],
    eligible_sites: { hospitals: 0, clinics: 3000 },
    performing_specialty: ['Endocrinology', 'Diabetes Care'],
    adoption_barrier: 'moderate',
    procedure_source: 'Insulet / Tandem investor presentations; ATTD Conference 2024',
    reimbursement: {
      cms_coverage: 'covered',
      private_payer_coverage: 'Commercial coverage for T1D broad. T2D coverage improving. AID systems (hybrid closed loop) gaining coverage.',
    },
    major_device_competitors: [
      'Omnipod 5 (Insulet) — tubeless AID',
      'Control-IQ (Tandem) — tubed AID',
      'MiniMed 780G (Medtronic)',
    ],
    market_leader: 'Insulet (Omnipod platform)',
    market_leader_share_pct: 38,
    current_standard_of_care: 'Automated insulin delivery (AID/hybrid closed loop) becoming standard over traditional pump therapy',
    cagr_5yr: 8.0,
    growth_driver: 'AID system adoption, tubeless design expansion, Type 2 indication expansion, pediatric use',
  },

  // ──────────────────────────────────────────────────────────
  // ONCOLOGY — SURGICAL / ROBOTIC
  // ──────────────────────────────────────────────────────────

  {
    name: 'Robotic-Assisted Radical Prostatectomy',
    synonyms: ['RARP', 'robotic prostatectomy', 'da Vinci prostatectomy', 'laparoscopic radical prostatectomy'],
    cpt_codes: ['55866', '55840', '55845'],
    drg_codes: ['710', '711', '712'],
    device_category: 'oncology_surgical',
    us_annual_procedures: 120000,
    us_procedure_growth_rate: 3.5,
    procedure_setting: ['hospital_inpatient', 'hospital_outpatient', 'asc'],
    eligible_sites: { hospitals: 3000, ascs: 200 },
    performing_specialty: ['Urology'],
    adoption_barrier: 'low',
    procedure_source: 'AUA Data 2024; SEER prostate cancer treatment patterns',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 11000,
      medicare_physician_rate: 1800,
      private_payer_coverage: 'Universal commercial coverage. Robotic approach not separately reimbursed but accepted.',
    },
    major_device_competitors: [
      'da Vinci (Intuitive Surgical) — dominant',
      'Hugo RAS (Medtronic) — emerging',
      'Ion (Intuitive) — for lung biopsy',
      'Versius (CMR Surgical) — EU/emerging markets',
    ],
    market_leader: 'Intuitive Surgical (da Vinci)',
    market_leader_share_pct: 82,
    current_standard_of_care: 'Robotic-assisted (RARP) is now standard; >85% of prostatectomies are robot-assisted',
    cagr_5yr: 3.5,
    growth_driver: 'Expanded robotic systems, SP (single port) adoption, bladder and kidney procedures, competitive robotic entry',
  },

  // ──────────────────────────────────────────────────────────
  // DIAGNOSTICS — IVD / ONCOLOGY
  // ──────────────────────────────────────────────────────────

  {
    name: 'Next-Generation Sequencing Oncology Panel',
    synonyms: ['NGS tumor profiling', 'comprehensive genomic profiling', 'CGP', 'tumor sequencing', 'solid tumor NGS', 'liquid biopsy NGS'],
    cpt_codes: ['81445', '81455', '81479', '0242U', '0244U'],
    drg_codes: [],
    device_category: 'ivd_oncology',
    us_annual_procedures: 800000,
    us_procedure_growth_rate: 22.0,
    procedure_setting: ['lab'],
    eligible_sites: { labs: 200, hospitals: 500 },
    performing_specialty: ['Medical Oncology', 'Pathology', 'Molecular Pathology'],
    adoption_barrier: 'moderate',
    procedure_source: 'NCCN Guidelines Biomarker Testing; Foundation Medicine data 2024',
    reimbursement: {
      cms_coverage: 'partial',
      medicare_facility_rate: 600,     // Tissue NGS panel; liquid biopsy varies
      private_payer_coverage: 'Highly variable. Foundation Medicine F1CDx covered by Medicare when ordered for FDA-approved CDx indication. Broader CGP coverage varies by payer. Most major commercial payers now cover for approved indications (NSCLC, breast, colorectal, ovarian).',
    },
    major_device_competitors: [
      'FoundationOne CDx (Roche/Foundation Medicine)',
      'Guardant360 CDx (Guardant Health)',
      'Tempus xT (Tempus)',
      'Caris MI Profile (Caris Life Sciences)',
      'OncotypeDX (Exact Sciences)',
    ],
    market_leader: 'Roche / Foundation Medicine',
    market_leader_share_pct: 30,
    current_standard_of_care: 'NCCN recommends broad molecular profiling for NSCLC, colorectal, ovarian, and other solid tumors. Liquid biopsy gaining traction for monitoring and when tissue unavailable.',
    cagr_5yr: 22.0,
    growth_driver: 'NCCN guideline expansion, CDx approvals requiring testing, liquid biopsy adoption, Medicare coverage expansion, MRD monitoring',
  },

  {
    name: 'Liquid Biopsy for Cancer Detection',
    synonyms: ['ctDNA testing', 'circulating tumor DNA', 'cell-free DNA', 'cfDNA cancer test', 'Galleri', 'multi-cancer early detection'],
    cpt_codes: ['0242U', '81479', '81503'],
    drg_codes: [],
    device_category: 'ivd_oncology',
    us_annual_procedures: 500000,
    us_procedure_growth_rate: 45.0,
    procedure_setting: ['lab', 'office'],
    eligible_sites: { hospitals: 0, labs: 100, clinics: 10000 },
    performing_specialty: ['Primary Care', 'Medical Oncology', 'Internal Medicine'],
    adoption_barrier: 'high',   // Reimbursement still being established
    procedure_source: 'Grail / Guardant investor data 2024; CMS Coverage Analysis',
    reimbursement: {
      cms_coverage: 'unlisted',  // CMS has not yet established national coverage for MCED
      private_payer_coverage: 'Mostly not covered. CMS proposed coverage determination for Galleri ongoing. Individual payer pilots. Self-pay at $950-$1,200. Critical regulatory/coverage milestone for market growth.',
    },
    major_device_competitors: [
      'Galleri (Grail/Illumina)',
      'Shield (Guardant Health) — CRC screening; FDA approved',
      'CancerSEEK (Johns Hopkins, Exact Sciences)',
      'Signatera (Natera) — MRD monitoring',
      'Cobas ctDNA (Roche)',
    ],
    market_leader: 'Grail (Galleri) for MCED; Guardant for therapy monitoring',
    market_leader_share_pct: 35,
    current_standard_of_care: 'Emerging — not yet standard of care for screening. MRD monitoring (post-treatment) gaining adoption. CRC blood test (Shield) first FDA-approved blood-based cancer screening test (2024).',
    cagr_5yr: 45.0,
    growth_driver: 'CMS national coverage decision for MCED, CRC blood test expansion, MRD-guided treatment decisions, early cancer interception opportunity',
  },

  // ──────────────────────────────────────────────────────────
  // NEUROLOGY DEVICES
  // ──────────────────────────────────────────────────────────

  {
    name: 'Deep Brain Stimulation',
    synonyms: ["DBS", "deep brain stimulation", "subthalamic nucleus stimulation", "DBS for Parkinson's"],
    cpt_codes: ['61863', '61864', '61885', '61886', '95970', '95971'],
    drg_codes: ['040', '041', '042'],
    device_category: 'neurology',
    us_annual_procedures: 16000,
    us_procedure_growth_rate: 6.0,
    procedure_setting: ['hospital_inpatient'],
    eligible_sites: { hospitals: 350 },
    performing_specialty: ['Neurosurgery', 'Neurology'],
    adoption_barrier: 'high',
    procedure_source: 'Medtronic/Abbott DBS commercial data; published registry data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 28000,
      medicare_physician_rate: 3500,
      private_payer_coverage: "Coverage for Parkinson's disease broad; expanding to Essential Tremor, OCD, epilepsy. Prior auth required.",
    },
    major_device_competitors: [
      "Percept PC (Medtronic) — sensing + stimulation",
      "Infinity DBS (Abbott)",
      "Vercise (Boston Scientific)",
      "Clarise (Nalu Medical) — emerging",
    ],
    market_leader: 'Medtronic',
    market_leader_share_pct: 55,
    current_standard_of_care: "DBS for Parkinson's (STN or GPi targets). Closed-loop (sensing) systems emerging as next-gen.",
    cagr_5yr: 6.0,
    growth_driver: 'Expanded indications (depression, OCD, Alzheimer pilot, epilepsy), closed-loop adaptive DBS, directional leads, rechargeable IPG',
  },

  // ──────────────────────────────────────────────────────────
  // OPHTHALMOLOGY
  // ──────────────────────────────────────────────────────────

  {
    name: 'Cataract Surgery with IOL Implantation',
    synonyms: ['phacoemulsification', 'cataract removal', 'IOL implant', 'intraocular lens', 'LASIK'],
    cpt_codes: ['66984', '66982', '66985'],
    drg_codes: [],
    device_category: 'ophthalmology',
    us_annual_procedures: 4000000,
    us_procedure_growth_rate: 3.5,
    procedure_setting: ['asc', 'hospital_outpatient'],
    eligible_sites: { ascs: 6000, hospitals: 2000 },
    performing_specialty: ['Ophthalmology'],
    adoption_barrier: 'low',
    procedure_source: 'AAO Market Study 2024; CMS Procedure Data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 1200,
      medicare_physician_rate: 750,
      private_payer_coverage: 'Universal coverage. Premium IOLs (multifocal, extended depth of focus) are patient out-of-pocket.',
    },
    major_device_competitors: [
      'Alcon (Centurion phaco + AcrySof IOL)',
      'Johnson & Johnson Vision (TECNIS)',
      'Bausch & Lomb (Stellaris + enVista)',
      'Rayner (UK)',
    ],
    market_leader: 'Alcon',
    market_leader_share_pct: 42,
    current_standard_of_care: 'Phacoemulsification with foldable hydrophilic or hydrophobic acrylic IOL. Premium IOLs (EDOF, toric) growing.',
    cagr_5yr: 3.5,
    growth_driver: 'Aging population, premium IOL adoption, femtosecond laser-assisted cataract surgery, light-adjustable lens',
  },

  {
    name: 'Anti-VEGF Intravitreal Injection',
    synonyms: ['intravitreal injection', 'anti-VEGF injection', 'Eylea injection', 'Avastin injection', 'Lucentis injection', 'Vabysmo injection'],
    cpt_codes: ['67028'],
    drg_codes: [],
    device_category: 'ophthalmology',
    us_annual_procedures: 9000000,
    us_procedure_growth_rate: 6.0,
    procedure_setting: ['office', 'hospital_outpatient'],
    eligible_sites: { clinics: 8000, hospitals: 500 },
    performing_specialty: ['Retina Specialist', 'Ophthalmology'],
    adoption_barrier: 'low',
    procedure_source: 'Regeneron investor data; CMS Part B Drug Spending 2024',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_physician_rate: 80,     // Procedure fee; drug reimbursed separately (ASP + 6%)
      private_payer_coverage: 'Universal coverage. Drug cost is primary cost driver (ASP-based Medicare reimbursement).',
    },
    major_device_competitors: [
      'Eylea 2mg (Regeneron) — market leader',
      'Eylea HD 8mg (Regeneron)',
      'Vabysmo (Roche)',
      'Lucentis/biosimilars (Genentech/Novartis)',
      'Beovu (Novartis)',
    ],
    market_leader: 'Regeneron (Eylea)',
    market_leader_share_pct: 50,
    current_standard_of_care: 'Monthly to quarterly intravitreal injections for nAMD, DME, RVO. Extended dosing intervals (Eylea HD, Vabysmo) driving toward quarterly/biannual dosing.',
    cagr_5yr: 6.0,
    growth_driver: 'Extended dosing intervals reducing injection burden, geographic atrophy new treatment market, port delivery system avoiding injections',
  },

  // ──────────────────────────────────────────────────────────
  // WOUND CARE
  // ──────────────────────────────────────────────────────────

  {
    name: 'Negative Pressure Wound Therapy',
    synonyms: ['NPWT', 'VAC therapy', 'wound VAC', 'negative pressure therapy', 'KCI NPWT'],
    cpt_codes: ['97605', '97606', 'E2402'],
    drg_codes: [],
    device_category: 'wound_care',
    us_annual_procedures: 1500000,
    us_procedure_growth_rate: 5.0,
    procedure_setting: ['hospital_inpatient', 'hospital_outpatient', 'home'],
    eligible_sites: { hospitals: 4500, clinics: 2000 },
    performing_specialty: ['Wound Care', 'General Surgery', 'Plastic Surgery', 'Orthopedics'],
    adoption_barrier: 'low',
    procedure_source: 'CMS Wound Care Data 2024; 3M / KCI market data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 800,     // per week (rental model)
      private_payer_coverage: 'Broadly covered. Rental model; DME benefit for home use.',
    },
    major_device_competitors: [
      'Prevena/ActiV.A.C. (3M/KCI)',
      'AVANCE (Mölnlycke)',
      'Renasys (Smith+Nephew)',
      'Snap (Acelity/3M)',
    ],
    market_leader: '3M (KCI)',
    market_leader_share_pct: 60,
    current_standard_of_care: 'Standard of care for complex wounds, diabetic foot ulcers, post-surgical. Disposable single-use NPWT devices growing.',
    cagr_5yr: 5.0,
    growth_driver: 'Diabetic population growth, single-use disposable NPWT, closed incision NPWT (surgical prophylaxis), home use expansion',
  },

  // ──────────────────────────────────────────────────────────
  // CARDIOVASCULAR DEVICES (ADDITIONAL)
  // ──────────────────────────────────────────────────────────

  {
    name: 'Leadless Pacemaker Implantation',
    synonyms: ['Micra', 'leadless pacing', 'transcatheter pacemaker', 'single-chamber leadless pacemaker', 'Aveir'],
    cpt_codes: ['33274', '33275'],
    drg_codes: ['245', '246'],
    device_category: 'cardiovascular',
    us_annual_procedures: 45000,
    us_procedure_growth_rate: 15.0,
    procedure_setting: ['hospital_inpatient', 'hospital_outpatient'],
    eligible_sites: { hospitals: 1200 },
    performing_specialty: ['Cardiac Electrophysiology'],
    adoption_barrier: 'moderate',
    procedure_source: 'Medtronic Micra post-market registry 2024; HRS data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 22000,
      medicare_physician_rate: 1200,
      private_payer_coverage: 'Covered by major commercial payers. Leadless approach accepted as alternative to transvenous pacing.',
    },
    major_device_competitors: [
      'Micra AV / VR (Medtronic) — dominant',
      'Aveir VR / DR (Abbott) — dual-chamber emerging',
    ],
    market_leader: 'Medtronic (Micra)',
    market_leader_share_pct: 85,
    current_standard_of_care: 'Transvenous pacemakers remain majority of implants (~200K/yr total US pacemakers). Leadless growing rapidly, especially for single-chamber VVI pacing.',
    cagr_5yr: 15.0,
    growth_driver: 'Dual-chamber leadless systems (Aveir DR), elimination of lead-related complications, expanding to more pacing indications',
  },

  {
    name: 'Subcutaneous ICD Implantation',
    synonyms: ['S-ICD', 'subcutaneous implantable cardioverter defibrillator', 'EMBLEM S-ICD', 'extravascular ICD', 'EV-ICD'],
    cpt_codes: ['33270', '33271', '33272', '33273'],
    drg_codes: ['245', '246'],
    device_category: 'cardiovascular',
    us_annual_procedures: 18000,
    us_procedure_growth_rate: 8.0,
    procedure_setting: ['hospital_inpatient'],
    eligible_sites: { hospitals: 900 },
    performing_specialty: ['Cardiac Electrophysiology'],
    adoption_barrier: 'moderate',
    procedure_source: 'Boston Scientific S-ICD registry data 2024; HRS EP Lab Survey',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 35000,
      medicare_physician_rate: 1800,
      private_payer_coverage: 'Covered by most commercial payers. Criteria typically require SCD risk without pacing indication.',
    },
    major_device_competitors: [
      'EMBLEM S-ICD (Boston Scientific) — dominant',
      'Aurora EV-ICD (Medtronic) — next-generation extravascular',
    ],
    market_leader: 'Boston Scientific (EMBLEM)',
    market_leader_share_pct: 90,
    current_standard_of_care: 'Transvenous ICD remains standard (~70K US implants/yr total). S-ICD preferred when no pacing/ATP needed; avoids intravascular lead complications.',
    cagr_5yr: 8.0,
    growth_driver: 'EV-ICD with anti-tachycardia pacing capability, younger patient preference for lead-free systems, infection risk reduction',
  },

  {
    name: 'Transcatheter Mitral Valve Repair (TEER)',
    synonyms: ['MitraClip', 'TEER', 'transcatheter edge-to-edge repair', 'mitral valve clip', 'PASCAL', 'mitral regurgitation repair'],
    cpt_codes: ['33418', '33419'],
    drg_codes: ['273', '274'],
    device_category: 'cardiovascular',
    us_annual_procedures: 35000,
    us_procedure_growth_rate: 18.0,
    procedure_setting: ['hospital_inpatient'],
    eligible_sites: { hospitals: 650 },
    performing_specialty: ['Interventional Cardiology', 'Cardiac Surgery'],
    adoption_barrier: 'moderate',
    procedure_source: 'TVT Registry TEER data 2024; Abbott/Edwards investor presentations',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 38000,
      medicare_physician_rate: 2200,
      private_payer_coverage: 'Commercial coverage established for primary and secondary MR meeting clinical criteria (COAPT-like population). Prior auth required.',
    },
    major_device_competitors: [
      'MitraClip G4 (Abbott) — market leader',
      'PASCAL Precision (Edwards Lifesciences)',
      'AccuCinch (Ancora Heart) — emerging annuloplasty',
    ],
    market_leader: 'Abbott (MitraClip)',
    market_leader_share_pct: 75,
    current_standard_of_care: 'MitraClip dominant for transcatheter MR repair. Surgical mitral repair/replacement for operable patients. Large untreated MR population.',
    cagr_5yr: 18.0,
    growth_driver: 'Massive undertreated MR population (>2M in US), expanded indication criteria, PASCAL competitive entry, transcatheter mitral replacement on horizon',
  },

  {
    name: 'Left Atrial Appendage Closure',
    synonyms: ['LAAC', 'Watchman', 'LAA occlusion', 'left atrial appendage occlusion', 'LARIAT', 'Amulet'],
    cpt_codes: ['33340'],
    drg_codes: ['273', '274'],
    device_category: 'cardiovascular',
    us_annual_procedures: 65000,
    us_procedure_growth_rate: 14.0,
    procedure_setting: ['hospital_inpatient', 'hospital_outpatient'],
    eligible_sites: { hospitals: 800 },
    performing_specialty: ['Interventional Cardiology', 'Cardiac Electrophysiology'],
    adoption_barrier: 'moderate',
    procedure_source: 'Boston Scientific Watchman registry 2024; CMS NCD data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 28000,
      medicare_physician_rate: 1600,
      private_payer_coverage: 'Covered for AFib patients with contraindication or intolerance to long-term anticoagulation. CMS NCD established.',
    },
    major_device_competitors: [
      'Watchman FLX Pro (Boston Scientific) — dominant',
      'Amulet (Abbott)',
      'LAmbre (Lifetech Scientific) — China/EU',
    ],
    market_leader: 'Boston Scientific (Watchman)',
    market_leader_share_pct: 80,
    current_standard_of_care: 'Long-term oral anticoagulation (NOACs) for stroke prevention in AFib. LAAC alternative for patients who cannot tolerate anticoagulation.',
    cagr_5yr: 14.0,
    growth_driver: 'Expanding eligible population, combined AFib ablation + LAAC in single procedure, Amulet competitive entry, potential first-line indication',
  },

  {
    name: 'Coronary Artery Bypass Graft',
    synonyms: ['CABG', 'bypass surgery', 'coronary bypass', 'heart bypass', 'open heart surgery', 'OPCAB'],
    cpt_codes: ['33533', '33534', '33535', '33536'],
    drg_codes: ['231', '232', '233', '234', '235', '236'],
    device_category: 'cardiovascular',
    us_annual_procedures: 180000,
    us_procedure_growth_rate: -1.5,
    procedure_setting: ['hospital_inpatient'],
    eligible_sites: { hospitals: 1100 },
    performing_specialty: ['Cardiac Surgery'],
    adoption_barrier: 'low',
    procedure_source: 'STS Adult Cardiac Surgery Database 2024; AHA Statistics',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 42000,
      medicare_physician_rate: 3200,
      private_payer_coverage: 'Universal coverage. Well-established procedure with clear clinical guidelines.',
    },
    major_device_competitors: [
      'Vasoview (Getinge) — endoscopic vessel harvesting',
      'Cardioplegia systems (Medtronic)',
      'Heart-lung bypass machines (LivaNova, Getinge)',
      'Anastomotic connectors (Medtronic)',
      'Stabilization systems (Medtronic Octopus)',
    ],
    market_leader: 'Getinge/Medtronic (perfusion/stabilization)',
    market_leader_share_pct: 40,
    current_standard_of_care: 'On-pump CABG with internal mammary artery graft. Off-pump (OPCAB) declining. Minimally invasive CABG (MIDCAB) niche.',
    cagr_5yr: -1.5,
    growth_driver: 'Declining volume as PCI expands to complex disease. Growth in hybrid revascularization (CABG + PCI). Robotic-assisted CABG niche.',
  },

  {
    name: 'Peripheral Vascular Stenting/Intervention',
    synonyms: ['PVI', 'peripheral stenting', 'PAD intervention', 'superficial femoral artery stenting', 'SFA stenting', 'drug-coated balloon', 'DCB', 'atherectomy'],
    cpt_codes: ['37226', '37227', '37228', '37229', '37230', '37231'],
    drg_codes: ['253', '254', '255'],
    device_category: 'cardiovascular',
    us_annual_procedures: 320000,
    us_procedure_growth_rate: 5.0,
    procedure_setting: ['hospital_inpatient', 'hospital_outpatient'],
    eligible_sites: { hospitals: 1500, ascs: 200 },
    performing_specialty: ['Vascular Surgery', 'Interventional Radiology', 'Interventional Cardiology'],
    adoption_barrier: 'low',
    procedure_source: 'SVS VQI Registry 2024; CMS claims data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 10000,
      medicare_physician_rate: 900,
      private_payer_coverage: 'Broadly covered. Drug-coated balloons covered; paclitaxel safety concerns resolved. Atherectomy coverage requires clinical criteria.',
    },
    major_device_competitors: [
      'Eluvia DES (Boston Scientific)',
      'Zilver PTX (Cook Medical)',
      'IN.PACT Admiral DCB (Medtronic)',
      'Lutonix DCB (BD/Bard)',
      'Diamondback 360 (CSI/Boston Scientific) — atherectomy',
    ],
    market_leader: 'Medtronic (IN.PACT platform)',
    market_leader_share_pct: 28,
    current_standard_of_care: 'Drug-coated balloon angioplasty or drug-eluting stent for SFA lesions. Atherectomy for calcified disease. Plain balloon for infrapopliteal.',
    cagr_5yr: 5.0,
    growth_driver: 'Aging population with PAD, increasing diagnosis rates, office-based lab (OBL) growth, CLI/CLTI limb salvage procedures',
  },

  {
    name: 'Carotid Artery Stenting',
    synonyms: ['CAS', 'carotid stenting', 'transfemoral carotid stenting', 'TCAR', 'transcarotid artery revascularization'],
    cpt_codes: ['37215', '37216', '37217', '37218'],
    drg_codes: ['034', '035'],
    device_category: 'cardiovascular',
    us_annual_procedures: 30000,
    us_procedure_growth_rate: 6.0,
    procedure_setting: ['hospital_inpatient'],
    eligible_sites: { hospitals: 700 },
    performing_specialty: ['Vascular Surgery', 'Interventional Radiology', 'Interventional Cardiology', 'Neurosurgery'],
    adoption_barrier: 'moderate',
    procedure_source: 'SVS VQI Carotid Registry 2024; CMS MEDPAR data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 16000,
      medicare_physician_rate: 1400,
      private_payer_coverage: 'Covered for high surgical risk patients. TCAR gaining broader coverage. CMS NCD requires physician credentials and hospital criteria.',
    },
    major_device_competitors: [
      'ENROUTE Transcarotid NPS + Stent (Silk Road Medical/Boston Scientific)',
      'Wallstent (Boston Scientific)',
      'Acculink/Accunet (Abbott)',
      'Protege/SpiderFX (Medtronic)',
    ],
    market_leader: 'Silk Road Medical / Boston Scientific (TCAR)',
    market_leader_share_pct: 45,
    current_standard_of_care: 'Carotid endarterectomy (CEA) remains gold standard (~100K/yr). CAS/TCAR for high surgical risk. TCAR gaining share with lower stroke rates.',
    cagr_5yr: 6.0,
    growth_driver: 'TCAR technology adoption (lower stroke risk vs transfemoral CAS), expanding to standard risk patients, aging population',
  },

  {
    name: 'Renal Denervation',
    synonyms: ['RDN', 'renal artery denervation', 'Symplicity Spyral', 'Paradise', 'catheter-based renal denervation'],
    cpt_codes: ['32160'],
    drg_codes: [],
    device_category: 'cardiovascular',
    us_annual_procedures: 5000,
    us_procedure_growth_rate: 50.0,
    procedure_setting: ['hospital_outpatient'],
    eligible_sites: { hospitals: 300 },
    performing_specialty: ['Interventional Cardiology', 'Interventional Radiology'],
    adoption_barrier: 'high',
    procedure_source: 'Medtronic Symplicity Spyral FDA approval data 2024; early commercial adoption estimates',
    reimbursement: {
      cms_coverage: 'partial',
      medicare_facility_rate: 8000,
      private_payer_coverage: 'Emerging coverage. FDA approved Symplicity Spyral (Nov 2023). CMS NTAP application pending. Early commercial cases largely self-pay or covered under individual payer decisions.',
    },
    major_device_competitors: [
      'Symplicity Spyral (Medtronic) — FDA approved',
      'Paradise (Recor Medical/Otsuka) — ultrasound-based, FDA approved',
    ],
    market_leader: 'Medtronic (Symplicity Spyral)',
    market_leader_share_pct: 60,
    current_standard_of_care: 'Multi-drug antihypertensive therapy. RDN is additive for resistant/uncontrolled hypertension. Very early market.',
    cagr_5yr: 50.0,
    growth_driver: 'First FDA approvals in 2023-2024, massive uncontrolled hypertension population (>15M US), reimbursement establishment, real-world evidence generation',
  },

  {
    name: 'Transcatheter Tricuspid Valve Repair',
    synonyms: ['TTVR', 'tricuspid TEER', 'TriClip', 'tricuspid repair', 'transcatheter tricuspid intervention'],
    cpt_codes: ['33418', '33419'],
    drg_codes: ['273', '274'],
    device_category: 'cardiovascular',
    us_annual_procedures: 5000,
    us_procedure_growth_rate: 45.0,
    procedure_setting: ['hospital_inpatient'],
    eligible_sites: { hospitals: 300 },
    performing_specialty: ['Interventional Cardiology', 'Cardiac Surgery'],
    adoption_barrier: 'high',
    procedure_source: 'Abbott TriClip FDA approval data 2024; early commercial estimates',
    reimbursement: {
      cms_coverage: 'partial',
      medicare_facility_rate: 35000,
      medicare_physician_rate: 2200,
      private_payer_coverage: 'Emerging coverage. FDA approved TriClip (Jan 2024). NTAP granted for additional reimbursement. Prior auth required.',
    },
    major_device_competitors: [
      'TriClip G4 (Abbott) — FDA approved TEER',
      'PASCAL Precision (Edwards Lifesciences) — in trials',
      'Cardioband (Edwards) — transcatheter annuloplasty',
      'EVOQUE (Edwards) — transcatheter tricuspid replacement',
    ],
    market_leader: 'Abbott (TriClip)',
    market_leader_share_pct: 70,
    current_standard_of_care: 'Medical management (diuretics) for most TR patients. Surgical repair only done during concomitant left-sided surgery. Massive untreated population.',
    cagr_5yr: 45.0,
    growth_driver: 'First dedicated FDA-approved device (TriClip), >1.6M US patients with significant TR, historically untreated population, multiple competing devices in pipeline',
  },

  {
    name: 'Cardiac CRT-D Implantation',
    synonyms: ['CRT-D', 'cardiac resynchronization therapy defibrillator', 'biventricular ICD', 'CRT-P', 'biventricular pacing'],
    cpt_codes: ['33249', '33225', '33224'],
    drg_codes: ['245', '246'],
    device_category: 'cardiovascular',
    us_annual_procedures: 55000,
    us_procedure_growth_rate: 2.0,
    procedure_setting: ['hospital_inpatient'],
    eligible_sites: { hospitals: 1200 },
    performing_specialty: ['Cardiac Electrophysiology'],
    adoption_barrier: 'low',
    procedure_source: 'NCDR ICD Registry 2024; Medtronic/Abbott/BSC investor data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 40000,
      medicare_physician_rate: 2000,
      private_payer_coverage: 'Covered for guideline-indicated HF patients (LVEF <=35%, LBBB, QRS >=150ms). Prior auth typically required.',
    },
    major_device_competitors: [
      'Viva/Claria (Medtronic)',
      'Quadra Assura (Abbott)',
      'Resonate (Boston Scientific)',
    ],
    market_leader: 'Medtronic',
    market_leader_share_pct: 40,
    current_standard_of_care: 'CRT-D for HFrEF with LBBB and wide QRS. Conduction system pacing (His-bundle, LBBAP) emerging as alternative resynchronization strategy.',
    cagr_5yr: 2.0,
    growth_driver: 'Conduction system pacing as CRT alternative, left bundle branch area pacing adoption, stable HF population, guideline adherence improvement',
  },

  // ──────────────────────────────────────────────────────────
  // ORTHOPEDIC DEVICES (ADDITIONAL)
  // ──────────────────────────────────────────────────────────

  {
    name: 'Reverse Shoulder Arthroplasty',
    synonyms: ['RSA', 'reverse total shoulder', 'reverse shoulder replacement', 'rTSA'],
    cpt_codes: ['23472'],
    drg_codes: ['483', '484'],
    device_category: 'orthopedic',
    us_annual_procedures: 130000,
    us_procedure_growth_rate: 8.0,
    procedure_setting: ['hospital_inpatient', 'hospital_outpatient', 'asc'],
    eligible_sites: { hospitals: 2500, ascs: 800 },
    performing_specialty: ['Orthopedic Surgery'],
    adoption_barrier: 'low',
    procedure_source: 'AJRR 2024; AAOS Shoulder Registry data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 13000,
      medicare_physician_rate: 1500,
      private_payer_coverage: 'Universal commercial coverage. ASC setting coverage expanding. Faster growth than anatomic TSA.',
    },
    major_device_competitors: [
      'Comprehensive Reverse (Zimmer Biomet)',
      'DELTA XTEND (DePuy Synthes)',
      'Aequalis Perform (Stryker)',
      'Equinoxe (Exactech)',
      'SMR (Lima Corporate)',
    ],
    market_leader: 'Zimmer Biomet',
    market_leader_share_pct: 28,
    current_standard_of_care: 'RSA now represents >70% of all shoulder replacements (up from 30% in 2012). Expanded from rotator cuff arthropathy to proximal humerus fractures and OA.',
    cagr_5yr: 8.0,
    growth_driver: 'Expanding indications (fractures, revision, younger patients), ASC migration, improved implant design, aging population',
  },

  {
    name: 'Total Ankle Replacement',
    synonyms: ['TAR', 'total ankle arthroplasty', 'ankle replacement', 'TAA'],
    cpt_codes: ['27702'],
    drg_codes: ['470'],
    device_category: 'orthopedic',
    us_annual_procedures: 16000,
    us_procedure_growth_rate: 12.0,
    procedure_setting: ['hospital_inpatient', 'hospital_outpatient'],
    eligible_sites: { hospitals: 800, ascs: 100 },
    performing_specialty: ['Orthopedic Surgery', 'Foot and Ankle Surgery'],
    adoption_barrier: 'moderate',
    procedure_source: 'AOFAS Registry 2024; Stryker/Integra investor data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 13000,
      medicare_physician_rate: 1400,
      private_payer_coverage: 'Covered by major commercial payers. Historically limited to post-arthrodesis failure; now accepted as primary treatment for end-stage ankle arthritis.',
    },
    major_device_competitors: [
      'STAR (Stryker)',
      'INFINITY (Wright Medical/Stryker)',
      'Cadence (Integra)',
      'INBONE II (Wright Medical/Stryker)',
      'Vantage (Exactech)',
    ],
    market_leader: 'Stryker (STAR + Wright platforms)',
    market_leader_share_pct: 45,
    current_standard_of_care: 'Ankle arthrodesis (fusion) historically dominant. TAR gaining share as implant designs improve and outcomes data strengthens. Now ~40% of ankle arthritis surgical treatments.',
    cagr_5yr: 12.0,
    growth_driver: 'Improved implant survivorship, surgeon training programs, patient preference for motion preservation, expansion beyond specialty centers',
  },

  {
    name: 'Rotator Cuff Repair (Arthroscopic)',
    synonyms: ['rotator cuff repair', 'arthroscopic RCR', 'shoulder arthroscopy', 'supraspinatus repair', 'rotator cuff surgery'],
    cpt_codes: ['29827', '23412', '23420'],
    drg_codes: ['483', '484'],
    device_category: 'orthopedic',
    us_annual_procedures: 460000,
    us_procedure_growth_rate: 3.0,
    procedure_setting: ['hospital_outpatient', 'asc'],
    eligible_sites: { hospitals: 3000, ascs: 3500 },
    performing_specialty: ['Orthopedic Surgery', 'Sports Medicine'],
    adoption_barrier: 'low',
    procedure_source: 'AAOS Clinical Data Registry 2024; Arthrex/Smith+Nephew investor data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 5500,
      medicare_physician_rate: 900,
      private_payer_coverage: 'Universal coverage. Conservative treatment failure typically required. Imaging confirmation (MRI) standard.',
    },
    major_device_competitors: [
      'Arthrex (SutureBridge, SpeedBridge) — dominant',
      'Smith+Nephew (HEALICOIL)',
      'Stryker (CrossFT)',
      'DePuy Mitek/J&J (GRYPHON)',
      'Zimmer Biomet (JuggerKnot)',
    ],
    market_leader: 'Arthrex',
    market_leader_share_pct: 45,
    current_standard_of_care: 'Arthroscopic repair with suture anchor fixation. Double-row repair preferred for large tears. Biologic augmentation (patches, PRP) emerging.',
    cagr_5yr: 3.0,
    growth_driver: 'Biologic augmentation products, active aging population, improved anchor technology, ASC migration',
  },

  {
    name: 'Vertebral Compression Fracture Treatment (Kyphoplasty/Vertebroplasty)',
    synonyms: ['kyphoplasty', 'vertebroplasty', 'balloon kyphoplasty', 'VCF treatment', 'vertebral augmentation', 'SpineJack'],
    cpt_codes: ['22513', '22514', '22510', '22511'],
    drg_codes: ['459', '460'],
    device_category: 'orthopedic',
    us_annual_procedures: 100000,
    us_procedure_growth_rate: 3.0,
    procedure_setting: ['hospital_outpatient', 'asc', 'hospital_inpatient'],
    eligible_sites: { hospitals: 2000, ascs: 500 },
    performing_specialty: ['Interventional Radiology', 'Neurosurgery', 'Orthopedic Surgery', 'Pain Medicine'],
    adoption_barrier: 'low',
    procedure_source: 'CMS claims data 2024; Medtronic/Stryker investor data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 4500,
      medicare_physician_rate: 600,
      private_payer_coverage: 'Covered for symptomatic VCFs failing conservative management. Some payers require 4-6 weeks conservative treatment first.',
    },
    major_device_competitors: [
      'Kyphon (Medtronic) — balloon kyphoplasty',
      'iVAS (Stryker) — vertebral augmentation',
      'SpineJack (Stryker) — titanium implant',
      'KIVA (Benvenue Medical)',
      'CareFusion (BD) — vertebroplasty needles',
    ],
    market_leader: 'Medtronic (Kyphon)',
    market_leader_share_pct: 50,
    current_standard_of_care: 'Balloon kyphoplasty most common surgical option. PMMA cement injection. Growing use of implantable devices (SpineJack) for height restoration.',
    cagr_5yr: 3.0,
    growth_driver: 'Aging osteoporotic population, ambulatory setting shift, implantable augmentation devices, interventional radiology adoption',
  },

  {
    name: 'ACL Reconstruction',
    synonyms: ['anterior cruciate ligament reconstruction', 'ACL repair', 'ACL surgery', 'ACLR', 'knee ligament reconstruction'],
    cpt_codes: ['29888'],
    drg_codes: ['483', '484'],
    device_category: 'orthopedic',
    us_annual_procedures: 200000,
    us_procedure_growth_rate: 2.5,
    procedure_setting: ['hospital_outpatient', 'asc'],
    eligible_sites: { hospitals: 2500, ascs: 3000 },
    performing_specialty: ['Orthopedic Surgery', 'Sports Medicine'],
    adoption_barrier: 'low',
    procedure_source: 'AAOS/AOSSM Registry 2024; Arthrex/Smith+Nephew investor data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 6000,
      medicare_physician_rate: 1100,
      private_payer_coverage: 'Universal commercial coverage. No prior auth typically needed for acute ACL tears with instability.',
    },
    major_device_competitors: [
      'Arthrex (TightRope, ACL repair kits)',
      'Smith+Nephew (ENDOBUTTON)',
      'DePuy Mitek/J&J (RIGIDFIX)',
      'Stryker (CrossPin)',
      'Zimmer Biomet (ToggleLoc)',
    ],
    market_leader: 'Arthrex',
    market_leader_share_pct: 40,
    current_standard_of_care: 'Arthroscopic reconstruction with autograft (BTB or hamstring) or allograft. Suspensory fixation growing. ACL repair (InternalBrace) emerging for proximal tears.',
    cagr_5yr: 2.5,
    growth_driver: 'Growing sports participation, ACL repair vs reconstruction debate, biologic augmentation, improved graft fixation technology',
  },

  // ──────────────────────────────────────────────────────────
  // NEUROLOGY DEVICES (ADDITIONAL)
  // ──────────────────────────────────────────────────────────

  {
    name: 'Vagus Nerve Stimulation',
    synonyms: ['VNS', 'vagus nerve stimulator', 'VNS therapy', 'vagal nerve stimulation', 'LivaNova VNS'],
    cpt_codes: ['64568', '64569', '64570', '95970', '95971'],
    drg_codes: ['040', '041', '042'],
    device_category: 'neurology',
    us_annual_procedures: 8000,
    us_procedure_growth_rate: 4.0,
    procedure_setting: ['hospital_outpatient', 'hospital_inpatient'],
    eligible_sites: { hospitals: 500 },
    performing_specialty: ['Neurosurgery', 'Neurology'],
    adoption_barrier: 'moderate',
    procedure_source: 'LivaNova investor presentations 2024; published epilepsy registry data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 18000,
      medicare_physician_rate: 1200,
      private_payer_coverage: 'Covered for drug-resistant epilepsy (DRE) after 2+ AED failures. Treatment-resistant depression coverage variable and often denied.',
    },
    major_device_competitors: [
      'VNS Therapy SenTiva (LivaNova) — dominant',
      'gammaCore (electroCore) — non-invasive VNS for headache',
    ],
    market_leader: 'LivaNova',
    market_leader_share_pct: 95,
    current_standard_of_care: 'Adjunctive therapy for drug-resistant epilepsy. Also FDA-approved for treatment-resistant depression. Implanted generator with vagus nerve electrode.',
    cagr_5yr: 4.0,
    growth_driver: 'Improved patient selection, new autodetection/responsive stimulation, expanded depression indications, pediatric epilepsy use',
  },

  {
    name: 'Spinal Cord Stimulation',
    synonyms: ['SCS', 'spinal cord stimulator', 'dorsal column stimulation', 'HF10', 'burst stimulation', 'closed-loop SCS'],
    cpt_codes: ['63650', '63655', '63685', '63688', '95972'],
    drg_codes: ['040', '041', '042'],
    device_category: 'neurology',
    us_annual_procedures: 50000,
    us_procedure_growth_rate: 3.0,
    procedure_setting: ['hospital_outpatient', 'asc'],
    eligible_sites: { hospitals: 1200, ascs: 400 },
    performing_specialty: ['Pain Medicine', 'Neurosurgery', 'Anesthesiology'],
    adoption_barrier: 'moderate',
    procedure_source: 'Medtronic/Abbott/BSC SCS investor data 2024; NACC Pain Registry',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 22000,
      medicare_physician_rate: 1500,
      private_payer_coverage: 'Covered for failed back surgery syndrome, CRPS, and chronic intractable pain. Trial stimulation required before permanent implant. Prior auth standard.',
    },
    major_device_competitors: [
      'Intellis/Vanta (Medtronic) — closed-loop',
      'Proclaim XR (Abbott)',
      'WaveWriter Alpha (Boston Scientific)',
      'Senza (Nevro) — HF10 high-frequency',
      'Nalu Neurostimulation (Nalu Medical) — miniaturized',
    ],
    market_leader: 'Medtronic',
    market_leader_share_pct: 30,
    current_standard_of_care: 'Trial stimulation followed by permanent IPG implant. High-frequency (10kHz), burst, and closed-loop waveforms gaining share over traditional tonic stimulation.',
    cagr_5yr: 3.0,
    growth_driver: 'Closed-loop (ECAP-controlled) stimulation, non-surgical DRG stimulation, expanded pain indications, opioid alternative positioning',
  },

  {
    name: 'Transcranial Magnetic Stimulation',
    synonyms: ['TMS', 'rTMS', 'repetitive transcranial magnetic stimulation', 'deep TMS', 'NeuroStar', 'BrainsWay'],
    cpt_codes: ['90867', '90868', '90869'],
    drg_codes: [],
    device_category: 'neurology',
    us_annual_procedures: 120000,
    us_procedure_growth_rate: 15.0,
    procedure_setting: ['office'],
    eligible_sites: { hospitals: 0, clinics: 2500 },
    performing_specialty: ['Psychiatry', 'Neurology'],
    adoption_barrier: 'moderate',
    procedure_source: 'Neuronetics/BrainsWay investor presentations 2024; APA Treatment Guidelines',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_physician_rate: 165,    // Per session; full course = ~36 sessions
      private_payer_coverage: 'Coverage improving. Most major commercial payers cover for treatment-resistant MDD after 2+ antidepressant failures. OCD coverage expanding. Accelerated (theta burst) protocols gaining coverage.',
    },
    major_device_competitors: [
      'NeuroStar (Neuronetics) — largest installed base',
      'Deep TMS (BrainsWay) — helmet coil',
      'MagVenture (MagVenture)',
      'Apollo TMS (MagVita/Nexstim)',
      'CloudTMS (Magstim)',
    ],
    market_leader: 'Neuronetics (NeuroStar)',
    market_leader_share_pct: 40,
    current_standard_of_care: 'FDA-cleared for MDD, OCD, anxious depression, smoking cessation. Typical course: 36 sessions over 9 weeks. Theta burst (3-minute sessions) disrupting standard protocols.',
    cagr_5yr: 15.0,
    growth_driver: 'Theta burst protocol efficiency (3 min vs 37 min), expanded indications (PTSD, substance use, bipolar), growing mental health demand, practice model economics',
  },

  {
    name: 'Responsive Neurostimulation',
    synonyms: ['RNS', 'responsive neurostimulation system', 'NeuroPace', 'closed-loop brain stimulation', 'direct brain stimulation epilepsy'],
    cpt_codes: ['61850', '61860', '61863', '95836'],
    drg_codes: ['040', '041', '042'],
    device_category: 'neurology',
    us_annual_procedures: 2500,
    us_procedure_growth_rate: 10.0,
    procedure_setting: ['hospital_inpatient'],
    eligible_sites: { hospitals: 200 },
    performing_specialty: ['Neurosurgery', 'Neurology'],
    adoption_barrier: 'high',
    procedure_source: 'NeuroPace investor data 2024; AES conference data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 42000,
      medicare_physician_rate: 3800,
      private_payer_coverage: 'Covered for drug-resistant focal epilepsy with identifiable seizure foci. Requires comprehensive epilepsy center evaluation. Prior auth required.',
    },
    major_device_competitors: [
      'RNS System (NeuroPace) — only FDA-approved device',
    ],
    market_leader: 'NeuroPace',
    market_leader_share_pct: 100,
    current_standard_of_care: 'Only closed-loop brain-responsive neurostimulation system. For patients with drug-resistant focal epilepsy who are not candidates for resective surgery.',
    cagr_5yr: 10.0,
    growth_driver: 'Expanding epilepsy center adoption, long-term efficacy data showing progressive seizure reduction, potential expansion to bilateral temporal lobe epilepsy',
  },

  {
    name: 'Focused Ultrasound Thalamotomy',
    synonyms: ['FUS', 'MRgFUS', 'MRI-guided focused ultrasound', 'Exablate Neuro', 'focused ultrasound essential tremor', 'incisionless thalamotomy'],
    cpt_codes: ['0398T'],
    drg_codes: ['040', '041'],
    device_category: 'neurology',
    us_annual_procedures: 4000,
    us_procedure_growth_rate: 20.0,
    procedure_setting: ['hospital_outpatient'],
    eligible_sites: { hospitals: 100 },
    performing_specialty: ['Neurosurgery', 'Neurology'],
    adoption_barrier: 'high',
    procedure_source: 'Insightec investor data 2024; AANS/CNS conference data',
    reimbursement: {
      cms_coverage: 'partial',
      medicare_facility_rate: 30000,
      medicare_physician_rate: 2500,
      private_payer_coverage: 'Coverage improving. CMS covers for essential tremor. Commercial payer coverage variable; many require prior auth and failure of medication. Category III CPT code limits coverage.',
    },
    major_device_competitors: [
      'Exablate Neuro (Insightec) — only FDA-approved system',
    ],
    market_leader: 'Insightec',
    market_leader_share_pct: 100,
    current_standard_of_care: 'FDA-approved for essential tremor and tremor-dominant Parkinson disease. Incisionless, no implant. Requires MRI-compatible skull. DBS alternative for tremor.',
    cagr_5yr: 20.0,
    growth_driver: 'Additional indications (Parkinson tremor, neuropathic pain, epilepsy trials), capital installation expansion, patient preference for incisionless approach',
  },

  // ──────────────────────────────────────────────────────────
  // GENERAL SURGERY / GI / ENDOSCOPY
  // ──────────────────────────────────────────────────────────

  {
    name: 'Laparoscopic Cholecystectomy',
    synonyms: ['lap chole', 'laparoscopic gallbladder removal', 'cholecystectomy', 'gallbladder surgery', 'robotic cholecystectomy'],
    cpt_codes: ['47562', '47563', '47564'],
    drg_codes: ['416', '417', '418'],
    device_category: 'general_surgery',
    us_annual_procedures: 700000,
    us_procedure_growth_rate: 1.5,
    procedure_setting: ['hospital_outpatient', 'hospital_inpatient', 'asc'],
    eligible_sites: { hospitals: 4500, ascs: 2000 },
    performing_specialty: ['General Surgery'],
    adoption_barrier: 'low',
    procedure_source: 'NIS/HCUP 2024; CMS claims data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 5500,
      medicare_physician_rate: 700,
      private_payer_coverage: 'Universal coverage. One of the most commonly performed surgeries in the US.',
    },
    major_device_competitors: [
      'Ethicon Endo-Surgery (J&J) — trocars, energy devices',
      'Medtronic (Ligasure, stapling)',
      'Applied Medical (trocars, access)',
      'Intuitive Surgical (da Vinci for robotic)',
      'Stryker (camera systems)',
    ],
    market_leader: 'Ethicon (J&J)',
    market_leader_share_pct: 35,
    current_standard_of_care: 'Four-port laparoscopic cholecystectomy standard. Single-incision (SILS) niche. Robotic approach growing (~10% of cases). Fluorescence (ICG) cholangiography expanding.',
    cagr_5yr: 1.5,
    growth_driver: 'Mature market with modest growth. Innovation in single-port access, ICG fluorescence imaging, and ambulatory surgery shift',
  },

  {
    name: 'Bariatric Surgery (Sleeve Gastrectomy/Gastric Bypass)',
    synonyms: ['sleeve gastrectomy', 'gastric bypass', 'RYGB', 'Roux-en-Y', 'bariatric surgery', 'weight loss surgery', 'metabolic surgery', 'lap band'],
    cpt_codes: ['43775', '43644', '43645', '43659', '43842'],
    drg_codes: ['619', '620', '621'],
    device_category: 'general_surgery',
    us_annual_procedures: 280000,
    us_procedure_growth_rate: 5.0,
    procedure_setting: ['hospital_inpatient', 'hospital_outpatient'],
    eligible_sites: { hospitals: 1200 },
    performing_specialty: ['General Surgery', 'Bariatric Surgery'],
    adoption_barrier: 'moderate',
    procedure_source: 'MBSAQIP Registry 2024; ASMBS data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 14000,
      medicare_physician_rate: 1200,
      private_payer_coverage: 'Most commercial payers cover with BMI criteria (>=40, or >=35 with comorbidities). 6-12 month supervised diet often required. GLP-1 impact being monitored.',
    },
    major_device_competitors: [
      'Ethicon (J&J) — staplers, energy devices',
      'Medtronic — staplers, Signia platform',
      'Intuitive Surgical — robotic platform',
      'Applied Medical — trocars, access',
      'Apollo Endosurgery — endoscopic sleeve (ESG)',
    ],
    market_leader: 'Ethicon (J&J)',
    market_leader_share_pct: 40,
    current_standard_of_care: 'Laparoscopic sleeve gastrectomy (~60% of cases) and RYGB (~30%). Endoscopic sleeve gastroplasty emerging. GLP-1 agonists may reduce or supplement surgical volume.',
    cagr_5yr: 5.0,
    growth_driver: 'Obesity epidemic, expanded BMI criteria (2022 ASMBS guidelines), metabolic surgery for T2D, GLP-1 interaction (complementary not replacement)',
  },

  {
    name: 'Endoscopic Mucosal Resection',
    synonyms: ['EMR', 'endoscopic mucosal resection', 'polypectomy', 'endoscopic resection', 'piecemeal resection'],
    cpt_codes: ['43254', '44401', '45346'],
    drg_codes: [],
    device_category: 'endoscopy_gi',
    us_annual_procedures: 350000,
    us_procedure_growth_rate: 6.0,
    procedure_setting: ['hospital_outpatient', 'asc'],
    eligible_sites: { hospitals: 3000, ascs: 2500 },
    performing_specialty: ['Gastroenterology', 'Interventional Gastroenterology'],
    adoption_barrier: 'low',
    procedure_source: 'AGA Clinical Practice Updates 2024; CMS claims data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 2500,
      medicare_physician_rate: 450,
      private_payer_coverage: 'Universal coverage as part of endoscopic resection. Reimbursed alongside diagnostic endoscopy codes.',
    },
    major_device_competitors: [
      'Olympus — dominant endoscope platform',
      'Boston Scientific — EMR accessories',
      'Cook Medical — snares, injection needles',
      'Fujifilm — endoscopes',
      'ERBE — electrosurgical units',
    ],
    market_leader: 'Olympus',
    market_leader_share_pct: 60,
    current_standard_of_care: 'Standard for sessile polyps >20mm, flat colorectal lesions, and superficial GI neoplasia. Band ligation EMR for esophageal lesions.',
    cagr_5yr: 6.0,
    growth_driver: 'Colorectal cancer screening expansion, AI-assisted polyp detection, shift from surgery to endoscopic resection for early GI cancers',
  },

  {
    name: 'Endoscopic Submucosal Dissection',
    synonyms: ['ESD', 'endoscopic submucosal dissection', 'en bloc resection', 'submucosal dissection'],
    cpt_codes: ['43211', '44402', '45349'],
    drg_codes: [],
    device_category: 'endoscopy_gi',
    us_annual_procedures: 15000,
    us_procedure_growth_rate: 20.0,
    procedure_setting: ['hospital_outpatient', 'hospital_inpatient'],
    eligible_sites: { hospitals: 400 },
    performing_specialty: ['Interventional Gastroenterology'],
    adoption_barrier: 'high',
    procedure_source: 'ASGE survey data 2024; published ESD registries',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 4000,
      medicare_physician_rate: 700,
      private_payer_coverage: 'Covered when medically necessary. Reimbursement improving with dedicated CPT codes (2024). Prior auth may be required.',
    },
    major_device_competitors: [
      'Olympus — ESD knives and scopes',
      'Fujifilm — endoscopes',
      'ERBE — electrosurgical generators',
      'Boston Scientific — ESD accessories',
      'Ovesco — FTRD full-thickness resection',
    ],
    market_leader: 'Olympus',
    market_leader_share_pct: 55,
    current_standard_of_care: 'Gold standard for en bloc resection of large superficial GI neoplasms in Japan/Asia. US adoption growing rapidly but limited by training and expertise.',
    cagr_5yr: 20.0,
    growth_driver: 'US fellowship training expansion, dedicated CPT codes, organ-sparing approach for early GI cancers, robotic ESD platforms emerging',
  },

  {
    name: "Barrett's Esophagus Ablation",
    synonyms: ['radiofrequency ablation Barrett', 'RFA Barrett', 'BARRX', 'cryotherapy Barrett', 'esophageal ablation'],
    cpt_codes: ['43229', '43270'],
    drg_codes: [],
    device_category: 'endoscopy_gi',
    us_annual_procedures: 45000,
    us_procedure_growth_rate: 7.0,
    procedure_setting: ['hospital_outpatient', 'asc'],
    eligible_sites: { hospitals: 1200, ascs: 400 },
    performing_specialty: ['Gastroenterology'],
    adoption_barrier: 'low',
    procedure_source: 'Medtronic BARRX data 2024; AGA Barrett guidelines',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 3000,
      medicare_physician_rate: 500,
      private_payer_coverage: 'Covered for dysplastic Barrett esophagus. Non-dysplastic Barrett ablation coverage limited.',
    },
    major_device_competitors: [
      'BARRX RFA (Medtronic) — dominant',
      'C2 CryoBalloon (Pentax/C2 Therapeutics)',
      'truFreeze Spray Cryotherapy (CSA Medical)',
    ],
    market_leader: 'Medtronic (BARRX)',
    market_leader_share_pct: 70,
    current_standard_of_care: "Radiofrequency ablation with BARRX is standard for dysplastic Barrett's. Cryotherapy emerging as alternative. EMR for visible lesions followed by ablation of flat Barrett's.",
    cagr_5yr: 7.0,
    growth_driver: "Increased Barrett's surveillance and detection, cryotherapy as alternative modality, expanded guidelines for non-dysplastic ablation",
  },

  {
    name: 'ERCP with Stenting',
    synonyms: ['ERCP', 'endoscopic retrograde cholangiopancreatography', 'biliary stenting', 'pancreatic stenting', 'bile duct stenting'],
    cpt_codes: ['43260', '43262', '43274', '43275', '43276'],
    drg_codes: ['411', '412', '413'],
    device_category: 'endoscopy_gi',
    us_annual_procedures: 500000,
    us_procedure_growth_rate: 3.0,
    procedure_setting: ['hospital_outpatient', 'hospital_inpatient'],
    eligible_sites: { hospitals: 2500 },
    performing_specialty: ['Gastroenterology', 'Interventional Gastroenterology'],
    adoption_barrier: 'moderate',
    procedure_source: 'ASGE survey 2024; CMS procedure data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 4500,
      medicare_physician_rate: 600,
      private_payer_coverage: 'Universal coverage. Diagnostic and therapeutic ERCP well-established.',
    },
    major_device_competitors: [
      'Boston Scientific — dominant stent portfolio',
      'Olympus — duodenoscopes',
      'Cook Medical — stents, guidewires',
      'Medtronic — biliary devices',
      'Fujifilm — duodenoscopes',
    ],
    market_leader: 'Boston Scientific',
    market_leader_share_pct: 40,
    current_standard_of_care: 'Therapeutic ERCP for choledocholithiasis, biliary strictures, and pancreaticobiliary malignancies. Self-expanding metal stents for malignant obstruction.',
    cagr_5yr: 3.0,
    growth_driver: 'Aging population, increasing biliary disease, improved duodenoscope design (disposable tips), single-operator cholangioscopy (SpyGlass)',
  },

  {
    name: 'Hernia Repair (Mesh)',
    synonyms: ['inguinal hernia repair', 'ventral hernia repair', 'hernioplasty', 'laparoscopic hernia repair', 'robotic hernia repair', 'mesh herniorrhaphy'],
    cpt_codes: ['49505', '49507', '49560', '49561', '49652', '49653'],
    drg_codes: ['350', '351', '352', '353', '354', '355'],
    device_category: 'general_surgery',
    us_annual_procedures: 1100000,
    us_procedure_growth_rate: 2.0,
    procedure_setting: ['hospital_outpatient', 'asc', 'hospital_inpatient'],
    eligible_sites: { hospitals: 4500, ascs: 3000 },
    performing_specialty: ['General Surgery'],
    adoption_barrier: 'low',
    procedure_source: 'Americas Hernia Society Quality Collaborative 2024; CMS claims data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 4000,
      medicare_physician_rate: 600,
      private_payer_coverage: 'Universal coverage. Open, laparoscopic, and robotic approaches all covered. Mesh cost bundled into facility payment.',
    },
    major_device_competitors: [
      'Ethicon (J&J) — Prolene, Proceed, Physiomesh',
      'BD/Bard — Ventralex, Phasix (resorbable)',
      'Medtronic — ProGrip, Parietex',
      'Gore — GORE-TEX patches',
      'Intuitive Surgical — robotic platform',
    ],
    market_leader: 'Ethicon (J&J)',
    market_leader_share_pct: 30,
    current_standard_of_care: 'Tension-free mesh repair standard for inguinal and ventral hernias. Laparoscopic/robotic approaches growing for ventral hernias. Biologic and resorbable meshes for contaminated fields.',
    cagr_5yr: 2.0,
    growth_driver: 'Robotic hernia repair adoption, biologic/resorbable mesh innovation, obesity-related ventral hernias, AWR (abdominal wall reconstruction) subspecialty growth',
  },

  // ──────────────────────────────────────────────────────────
  // DIAGNOSTICS — IVD / ONCOLOGY / CARDIOLOGY (ADDITIONAL)
  // ──────────────────────────────────────────────────────────

  {
    name: 'Minimal Residual Disease Testing',
    synonyms: ['MRD testing', 'MRD', 'measurable residual disease', 'ctDNA MRD', 'Signatera', 'tumor-informed MRD'],
    cpt_codes: ['81479', '0239U', '0340U'],
    drg_codes: [],
    device_category: 'ivd_oncology',
    us_annual_procedures: 200000,
    us_procedure_growth_rate: 40.0,
    procedure_setting: ['lab'],
    eligible_sites: { labs: 80, hospitals: 200 },
    performing_specialty: ['Medical Oncology', 'Pathology', 'Hematology'],
    adoption_barrier: 'moderate',
    procedure_source: 'Natera/Guardant investor data 2024; NCCN MRD recommendations',
    reimbursement: {
      cms_coverage: 'partial',
      medicare_facility_rate: 450,
      private_payer_coverage: 'Emerging coverage. Medicare LCD for Signatera in CRC (MolDx). Commercial payer coverage variable. NCCN endorsement strengthening coverage arguments.',
    },
    major_device_competitors: [
      'Signatera (Natera) — tumor-informed, market leader',
      'Guardant Reveal (Guardant Health)',
      'RaDaR (NeoGenomics)',
      'FoundationOne Tracker (Foundation Medicine/Roche)',
      'Phased (Invivoscribe)',
    ],
    market_leader: 'Natera (Signatera)',
    market_leader_share_pct: 45,
    current_standard_of_care: 'Post-treatment surveillance via imaging and CEA/CA markers. ctDNA MRD testing enabling earlier recurrence detection (lead time 6-12 months vs imaging).',
    cagr_5yr: 40.0,
    growth_driver: 'NCCN guideline inclusion for CRC, expanding to breast/bladder/lung, MRD-guided adjuvant therapy decisions, clinical trial integration',
  },

  {
    name: 'HER2 IHC/FISH Testing',
    synonyms: ['HER2 testing', 'HER2 IHC', 'HER2 FISH', 'ERBB2 testing', 'HER2-low testing', 'HER2 ISH'],
    cpt_codes: ['88342', '88360', '88361', '88377'],
    drg_codes: [],
    device_category: 'ivd_oncology',
    us_annual_procedures: 600000,
    us_procedure_growth_rate: 8.0,
    procedure_setting: ['lab'],
    eligible_sites: { labs: 1500, hospitals: 2000 },
    performing_specialty: ['Pathology', 'Medical Oncology'],
    adoption_barrier: 'low',
    procedure_source: 'ASCO/CAP HER2 Guidelines 2024; Roche/Agilent investor data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 125,
      private_payer_coverage: 'Universal coverage for breast cancer. Expanding to gastric, CRC, NSCLC with new HER2-directed therapies (T-DXd). HER2-low identification driving retesting.',
    },
    major_device_competitors: [
      'PATHWAY (Roche/Ventana) — IHC, market leader',
      'HercepTest (Agilent/Dako)',
      'INFORM HER2 (Roche/Ventana) — FISH/ISH',
      'PathVysion (Abbott/Vysis) — FISH',
      'BOND Oracle (Leica)',
    ],
    market_leader: 'Roche/Ventana',
    market_leader_share_pct: 50,
    current_standard_of_care: 'IHC initial screening, FISH/ISH reflex for equivocal (2+) results. HER2-low (IHC 1+ or 2+/ISH-) now clinically actionable with T-DXd approval.',
    cagr_5yr: 8.0,
    growth_driver: 'HER2-low category driving expanded testing, T-DXd indication expansion, gastric/CRC/NSCLC HER2 testing, retesting at progression',
  },

  {
    name: 'PD-L1 IHC Testing',
    synonyms: ['PD-L1 testing', 'PD-L1 IHC', 'programmed death-ligand 1', 'TPS scoring', 'CPS scoring', 'PD-L1 companion diagnostic'],
    cpt_codes: ['88342', '88360'],
    drg_codes: [],
    device_category: 'ivd_oncology',
    us_annual_procedures: 550000,
    us_procedure_growth_rate: 6.0,
    procedure_setting: ['lab'],
    eligible_sites: { labs: 1200, hospitals: 1800 },
    performing_specialty: ['Pathology', 'Medical Oncology'],
    adoption_barrier: 'low',
    procedure_source: 'Agilent/Roche CDx data 2024; NCCN biomarker testing guidelines',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 110,
      private_payer_coverage: 'Universal coverage when used for FDA-approved checkpoint inhibitor selection. Multiple CDx assays approved with different antibodies and scoring systems.',
    },
    major_device_competitors: [
      'PD-L1 IHC 22C3 pharmDx (Agilent/Dako) — CDx for Keytruda',
      'SP263 (Roche/Ventana) — CDx for Imfinzi',
      'SP142 (Roche/Ventana) — CDx for Tecentriq',
      'PD-L1 IHC 28-8 pharmDx (Agilent/Dako) — CDx for Opdivo',
    ],
    market_leader: 'Agilent/Dako (22C3 for Keytruda)',
    market_leader_share_pct: 55,
    current_standard_of_care: 'Standard biomarker testing for IO therapy selection in NSCLC, head and neck, gastric, urothelial, cervical, and other solid tumors. TPS and CPS scoring methods.',
    cagr_5yr: 6.0,
    growth_driver: 'Expanding IO indications, IO combinations in earlier lines, harmonization of PD-L1 assays, TMB and other IO biomarkers as complement',
  },

  {
    name: 'BRCA1/2 Germline Testing',
    synonyms: ['BRCA testing', 'BRCA1/2', 'hereditary breast cancer testing', 'germline testing', 'BRACAnalysis', 'BRCA genetic testing'],
    cpt_codes: ['81162', '81163', '81164', '81165', '81166', '81167'],
    drg_codes: [],
    device_category: 'ivd_genetics',
    us_annual_procedures: 400000,
    us_procedure_growth_rate: 10.0,
    procedure_setting: ['lab', 'office'],
    eligible_sites: { hospitals: 0, labs: 500, clinics: 5000 },
    performing_specialty: ['Medical Oncology', 'Genetic Counseling', 'OB/GYN', 'Primary Care'],
    adoption_barrier: 'low',
    procedure_source: 'Myriad/Invitae investor data 2024; NCCN Genetic Testing Guidelines',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 600,
      private_payer_coverage: 'Covered for patients meeting NCCN criteria (family history, personal cancer history, Ashkenazi Jewish ancestry). Preventive Services mandate covers for some populations.',
    },
    major_device_competitors: [
      'BRACAnalysis CDx (Myriad Genetics) — FDA-approved CDx',
      'FoundationOne CDx (Roche) — includes BRCA',
      'Invitae Genetic Testing',
      'Color Genomics',
      'Ambry Genetics (Konica Minolta)',
    ],
    market_leader: 'Myriad Genetics',
    market_leader_share_pct: 40,
    current_standard_of_care: 'Germline BRCA testing standard for breast, ovarian, prostate, and pancreatic cancer. CDx for PARP inhibitor selection (olaparib, talazoparib, rucaparib).',
    cagr_5yr: 10.0,
    growth_driver: 'PARP inhibitor expansion, prostate cancer BRCA testing, pancreatic cancer guidelines, population-level screening advocacy, multigene panel adoption',
  },

  {
    name: 'Cardiac Troponin Point-of-Care Testing',
    synonyms: ['troponin POC', 'high-sensitivity troponin', 'hs-cTnI', 'hs-cTnT', 'cardiac troponin rapid test', 'i-STAT troponin'],
    cpt_codes: ['84484', '84485', '84512'],
    drg_codes: [],
    device_category: 'ivd_cardiology',
    us_annual_procedures: 25000000,
    us_procedure_growth_rate: 5.0,
    procedure_setting: ['hospital_inpatient', 'hospital_outpatient', 'office'],
    eligible_sites: { hospitals: 5000, clinics: 3000 },
    performing_specialty: ['Emergency Medicine', 'Cardiology', 'Internal Medicine'],
    adoption_barrier: 'low',
    procedure_source: 'Abbott/Roche/Siemens diagnostics data 2024; AACC guidance',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 18,
      private_payer_coverage: 'Universal coverage. Essential emergency diagnostic. Central lab hs-cTn and POC both covered.',
    },
    major_device_competitors: [
      'ARCHITECT hs-cTnI (Abbott) — central lab, dominant',
      'Elecsys hs-cTnT (Roche) — central lab',
      'Atellica hs-cTnI (Siemens)',
      'i-STAT TnI (Abbott) — POC',
      'Quidel Triage (QuidelOrtho) — POC',
    ],
    market_leader: 'Abbott (ARCHITECT + i-STAT platforms)',
    market_leader_share_pct: 35,
    current_standard_of_care: 'High-sensitivity cardiac troponin (hs-cTn) is guideline-mandated for MI diagnosis. Rapid rule-out protocols (0/1h or 0/3h) standard in EDs.',
    cagr_5yr: 5.0,
    growth_driver: 'POC hs-troponin adoption, rapid rule-out protocol expansion, decentralized testing in urgent care, combined cardiac biomarker panels',
  },

  {
    name: 'HbA1c Point-of-Care Testing',
    synonyms: ['HbA1c POC', 'hemoglobin A1c rapid', 'glycated hemoglobin POC', 'A1c test', 'DCA Vantage'],
    cpt_codes: ['83036', '83037'],
    drg_codes: [],
    device_category: 'diabetes_metabolic',
    us_annual_procedures: 18000000,
    us_procedure_growth_rate: 4.0,
    procedure_setting: ['office', 'lab'],
    eligible_sites: { hospitals: 0, clinics: 25000, labs: 5000 },
    performing_specialty: ['Primary Care', 'Endocrinology', 'Internal Medicine'],
    adoption_barrier: 'low',
    procedure_source: 'Siemens/Abbott POC diagnostics data 2024; ADA Standards of Care',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 12,
      private_payer_coverage: 'Universal coverage. ADA recommends at least 2x/year for controlled diabetes, quarterly for uncontrolled. CLIA-waived POC testing in physician offices.',
    },
    major_device_competitors: [
      'DCA Vantage (Siemens) — dominant POC',
      'Afinion 2 (Abbott)',
      'A1CNow (PTS Diagnostics)',
      'Cobas b 101 (Roche)',
      'NGSP-certified central lab assays',
    ],
    market_leader: 'Siemens (DCA Vantage)',
    market_leader_share_pct: 45,
    current_standard_of_care: 'HbA1c gold standard for diabetes management and diagnosis. POC testing enables same-visit clinical decisions. NGSP certification required.',
    cagr_5yr: 4.0,
    growth_driver: 'Growing diabetes population (38M+ US), POC adoption in primary care, same-visit decision-making value, prediabetes screening expansion',
  },

  {
    name: 'Sepsis Rapid Identification Panel',
    synonyms: ['sepsis rapid ID', 'blood culture ID', 'BCID', 'rapid pathogen identification', 'BioFire', 'Accelerate Pheno', 'T2Biosystems'],
    cpt_codes: ['87150', '87153', '87468', '87480', '87640', '87641'],
    drg_codes: [],
    device_category: 'ivd_infectious',
    us_annual_procedures: 3000000,
    us_procedure_growth_rate: 12.0,
    procedure_setting: ['lab', 'hospital_inpatient'],
    eligible_sites: { hospitals: 4000, labs: 1500 },
    performing_specialty: ['Infectious Disease', 'Clinical Microbiology', 'Critical Care'],
    adoption_barrier: 'moderate',
    procedure_source: 'bioMerieux/Becton Dickinson investor data 2024; CAP Microbiology Surveys',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 250,
      private_payer_coverage: 'Covered for FDA-cleared panels. CMS reimburses multiplex panels. Value proposition supported by antibiotic stewardship and sepsis bundle compliance.',
    },
    major_device_competitors: [
      'BioFire FilmArray BCID2 (bioMerieux) — dominant panel',
      'Verigene (Luminex/DiaSorin)',
      'Accelerate Pheno (Accelerate Diagnostics)',
      'T2Bacteria/Candida (T2 Biosystems) — direct from blood',
      'ePlex BCID (GenMark/Roche)',
    ],
    market_leader: 'bioMerieux (BioFire)',
    market_leader_share_pct: 55,
    current_standard_of_care: 'Blood culture with automated detection (BACTEC/BacT/ALERT) followed by rapid ID panel. Turnaround: 1-2 hours post-positive vs 24-48 hours for conventional ID.',
    cagr_5yr: 12.0,
    growth_driver: 'Sepsis mortality reduction initiatives, antimicrobial stewardship mandates, direct-from-blood testing, CMS SEP-1 bundle compliance, AST rapid phenotypic results',
  },

  {
    name: 'Digital Pathology AI-Assisted Reading',
    synonyms: ['digital pathology', 'AI pathology', 'computational pathology', 'whole slide imaging', 'WSI', 'AI-assisted diagnosis'],
    cpt_codes: ['88360', '88361', '0621T', '0622T'],
    drg_codes: [],
    device_category: 'imaging_radiology',
    us_annual_procedures: 500000,
    us_procedure_growth_rate: 35.0,
    procedure_setting: ['lab'],
    eligible_sites: { hospitals: 1000, labs: 500 },
    performing_specialty: ['Pathology', 'Dermatopathology'],
    adoption_barrier: 'high',
    procedure_source: 'Paige AI / PathAI / Philips investor data 2024; CAP Digital Pathology surveys',
    reimbursement: {
      cms_coverage: 'partial',
      medicare_facility_rate: 50,
      private_payer_coverage: 'Emerging. No separate reimbursement for AI-assisted reads in most cases; bundled into existing pathology CPT codes. Category III CPT codes (0621T, 0622T) for AI quantification.',
    },
    major_device_competitors: [
      'Paige AI (Paige) — first FDA-approved AI pathology',
      'PathAI (PathAI)',
      'Proscia (Philips partnership)',
      'Hamamatsu (scanners)',
      'Leica/Aperio (scanners, Leica Biosystems)',
      'Philips IntelliSite (scanner + viewer)',
    ],
    market_leader: 'Paige AI (for AI algorithms); Leica/Philips (for scanners)',
    market_leader_share_pct: 25,
    current_standard_of_care: 'Manual microscopy still dominant. Whole slide imaging (WSI) for primary diagnosis FDA-cleared since 2017. AI algorithms for prostate cancer detection, breast cancer HER2 scoring, and IHC quantification.',
    cagr_5yr: 35.0,
    growth_driver: 'Pathologist shortage, FDA clearances for AI algorithms, remote pathology demand, improved diagnostic accuracy, biomarker quantification automation',
  },

  // ──────────────────────────────────────────────────────────
  // VASCULAR
  // ──────────────────────────────────────────────────────────

  {
    name: 'Dialysis Access (AV Fistula/Graft Creation)',
    synonyms: ['AV fistula', 'arteriovenous fistula', 'AV graft', 'dialysis access', 'hemodialysis access', 'Ellipsys'],
    cpt_codes: ['36818', '36819', '36820', '36825', '36830'],
    drg_codes: ['673', '674'],
    device_category: 'renal_dialysis',
    us_annual_procedures: 120000,
    us_procedure_growth_rate: 3.0,
    procedure_setting: ['hospital_outpatient', 'asc'],
    eligible_sites: { hospitals: 2000, ascs: 600 },
    performing_specialty: ['Vascular Surgery', 'Interventional Radiology', 'Nephrology'],
    adoption_barrier: 'low',
    procedure_source: 'USRDS Annual Data Report 2024; CMS ESRD data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 6000,
      medicare_physician_rate: 800,
      private_payer_coverage: 'Universal coverage for ESRD patients. AV fistula preferred over graft per KDOQI guidelines. CMS Fistula First initiative.',
    },
    major_device_competitors: [
      'Ellipsys (Medtronic) — percutaneous AV fistula creation',
      'Gore (AV grafts, ACUSEAL)',
      'BD (dialysis catheters)',
      'Merit Medical (access devices)',
      'WavelinQ (BD) — endovascular AV fistula',
    ],
    market_leader: 'Gore (AV grafts); Medtronic (percutaneous AVF)',
    market_leader_share_pct: 35,
    current_standard_of_care: 'Surgical AV fistula creation remains standard. Percutaneous/endovascular AVF creation (Ellipsys, WavelinQ) emerging as less invasive alternative.',
    cagr_5yr: 3.0,
    growth_driver: 'Growing ESRD population, percutaneous AVF technology, home hemodialysis growth, AV fistula maintenance procedures',
  },

  {
    name: 'Endovascular Aneurysm Repair',
    synonyms: ['EVAR', 'endovascular aortic repair', 'aortic stent graft', 'TEVAR', 'thoracic endovascular repair', 'abdominal aortic aneurysm repair'],
    cpt_codes: ['34800', '34802', '34803', '34804', '34805', '34841', '34842'],
    drg_codes: ['237', '238', '239'],
    device_category: 'vascular',
    us_annual_procedures: 45000,
    us_procedure_growth_rate: 2.0,
    procedure_setting: ['hospital_inpatient'],
    eligible_sites: { hospitals: 1000 },
    performing_specialty: ['Vascular Surgery', 'Interventional Radiology', 'Cardiac Surgery'],
    adoption_barrier: 'low',
    procedure_source: 'SVS VQI AAA Registry 2024; Medtronic/Cook investor data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 32000,
      medicare_physician_rate: 2500,
      private_payer_coverage: 'Universal coverage. EVAR accepted as standard for anatomically suitable AAA. TEVAR for thoracic indications.',
    },
    major_device_competitors: [
      'Endurant II/IIs (Medtronic)',
      'Zenith (Cook Medical)',
      'AFX/Alto (Endologix)',
      'Excluder (Gore)',
      'Relay/Navion (Bolton Medical/Terumo)',
    ],
    market_leader: 'Medtronic (Endurant platform)',
    market_leader_share_pct: 35,
    current_standard_of_care: 'EVAR for infrarenal AAA with suitable anatomy (~75% of AAA repairs). Open surgical repair for complex anatomy. FEVAR/BEVAR for juxtarenal/thoracoabdominal.',
    cagr_5yr: 2.0,
    growth_driver: 'Fenestrated/branched EVAR for complex anatomy, TEVAR expansion for type B dissection, improved endograft durability, screening program growth',
  },

  {
    name: 'Venous Insufficiency Ablation',
    synonyms: ['varicose vein ablation', 'venous ablation', 'GSV ablation', 'endovenous laser ablation', 'EVLA', 'ClosureFast', 'radiofrequency ablation vein', 'VenaSeal'],
    cpt_codes: ['36475', '36476', '36478', '36479', '36482', '36483'],
    drg_codes: [],
    device_category: 'vascular',
    us_annual_procedures: 450000,
    us_procedure_growth_rate: 5.0,
    procedure_setting: ['office', 'asc'],
    eligible_sites: { hospitals: 0, clinics: 4000, ascs: 1500 },
    performing_specialty: ['Vascular Surgery', 'Interventional Radiology', 'Phlebology'],
    adoption_barrier: 'low',
    procedure_source: 'Medtronic/Medline vein data 2024; SVS VQI Varicose Vein Registry',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 2200,
      medicare_physician_rate: 400,
      private_payer_coverage: 'Covered for symptomatic venous insufficiency with documented reflux on duplex ultrasound. Conservative treatment trial (compression) typically required. Cosmetic varicose vein treatment not covered.',
    },
    major_device_competitors: [
      'ClosureFast (Medtronic) — radiofrequency, dominant',
      'VenaSeal (Medtronic) — cyanoacrylate adhesive',
      'Various laser fiber systems (AngioDynamics, Biolitec)',
      'Varithena (Boston Scientific) — polidocanol foam',
      'ClariVein (Merit Medical) — mechanochemical',
    ],
    market_leader: 'Medtronic (ClosureFast + VenaSeal)',
    market_leader_share_pct: 55,
    current_standard_of_care: 'Endovenous thermal ablation (RF or laser) standard for GSV insufficiency. Non-thermal (VenaSeal, ClariVein) growing — no tumescent anesthesia needed. Ambulatory office-based procedures.',
    cagr_5yr: 5.0,
    growth_driver: 'Non-thermal ablation adoption (VenaSeal), office-based lab growth, aging population, improved diagnosis rates',
  },

  // ──────────────────────────────────────────────────────────
  // PULMONARY / RESPIRATORY
  // ──────────────────────────────────────────────────────────

  {
    name: 'Bronchial Thermoplasty',
    synonyms: ['BT', 'bronchial thermoplasty', 'Alair', 'airway thermoplasty', 'asthma ablation'],
    cpt_codes: ['31660', '31661'],
    drg_codes: ['190', '191'],
    device_category: 'respiratory',
    us_annual_procedures: 3000,
    us_procedure_growth_rate: 5.0,
    procedure_setting: ['hospital_outpatient'],
    eligible_sites: { hospitals: 200 },
    performing_specialty: ['Pulmonology', 'Interventional Pulmonology'],
    adoption_barrier: 'high',
    procedure_source: 'Boston Scientific Alair data 2024; CHEST/ATS conference data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 8000,
      medicare_physician_rate: 900,
      private_payer_coverage: 'Variable coverage. Many commercial payers cover for severe persistent asthma uncontrolled on ICS/LABA. Prior auth required. Some payers still consider investigational.',
    },
    major_device_competitors: [
      'Alair (Boston Scientific) — only FDA-approved system',
    ],
    market_leader: 'Boston Scientific',
    market_leader_share_pct: 100,
    current_standard_of_care: 'Adjunct therapy for severe persistent asthma poorly controlled with ICS/LABA. Three bronchoscopy sessions required. Reduces smooth muscle mass in airways.',
    cagr_5yr: 5.0,
    growth_driver: 'Growing severe asthma population, improved patient selection criteria, biologic therapy non-responders, long-term durability data',
  },

  {
    name: 'Endobronchial Valve Placement (Zephyr)',
    synonyms: ['EBV', 'endobronchial valve', 'Zephyr valve', 'bronchoscopic lung volume reduction', 'BLVR', 'one-way valve emphysema'],
    cpt_codes: ['31647', '31651'],
    drg_codes: ['190', '191'],
    device_category: 'respiratory',
    us_annual_procedures: 6000,
    us_procedure_growth_rate: 15.0,
    procedure_setting: ['hospital_inpatient'],
    eligible_sites: { hospitals: 250 },
    performing_specialty: ['Interventional Pulmonology', 'Pulmonology'],
    adoption_barrier: 'high',
    procedure_source: 'Pulmonx Zephyr investor data 2024; CHEST/ATS guidelines',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 25000,
      medicare_physician_rate: 1500,
      private_payer_coverage: 'Improving coverage. CMS NCD established. Commercial payers increasingly covering with clinical criteria (severe emphysema, heterogeneous disease, no collateral ventilation).',
    },
    major_device_competitors: [
      'Zephyr Valve (Pulmonx) — only FDA-approved EBV',
    ],
    market_leader: 'Pulmonx',
    market_leader_share_pct: 100,
    current_standard_of_care: 'Bronchoscopic lung volume reduction for severe heterogeneous emphysema without collateral ventilation. Alternative to lung volume reduction surgery (LVRS).',
    cagr_5yr: 15.0,
    growth_driver: 'Growing physician training, CMS coverage establishment, Chartis assessment for patient selection, center of excellence expansion',
  },

  {
    name: 'Pulmonary Thrombectomy',
    synonyms: ['PE thrombectomy', 'pulmonary embolism thrombectomy', 'catheter-directed therapy PE', 'FlowTriever', 'EKOS', 'mechanical thrombectomy PE'],
    cpt_codes: ['37184', '37186', '37187', '37188'],
    drg_codes: ['175', '176', '177'],
    device_category: 'respiratory',
    us_annual_procedures: 20000,
    us_procedure_growth_rate: 25.0,
    procedure_setting: ['hospital_inpatient'],
    eligible_sites: { hospitals: 600 },
    performing_specialty: ['Interventional Radiology', 'Interventional Cardiology', 'Vascular Surgery', 'Pulmonary/Critical Care'],
    adoption_barrier: 'moderate',
    procedure_source: 'Inari Medical/Boston Scientific investor data 2024; PERT Consortium data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 20000,
      medicare_physician_rate: 1800,
      private_payer_coverage: 'Covered for massive and submassive PE. Growing acceptance as alternative to systemic thrombolysis. PERT (Pulmonary Embolism Response Team) programs driving utilization.',
    },
    major_device_competitors: [
      'FlowTriever (Inari Medical) — large bore aspiration, dominant',
      'ClotTriever (Inari Medical) — venous thrombectomy',
      'EKOS (Boston Scientific) — ultrasound-assisted CDT',
      'Indigo (Penumbra) — aspiration system',
      'AngioJet (Boston Scientific)',
    ],
    market_leader: 'Inari Medical (FlowTriever)',
    market_leader_share_pct: 50,
    current_standard_of_care: 'Systemic anticoagulation for most PE. Catheter-directed intervention for massive/high-risk submassive PE. Large bore aspiration thrombectomy (FlowTriever) growing rapidly.',
    cagr_5yr: 25.0,
    growth_driver: 'PERT team proliferation, FlowTriever clinical data, avoiding systemic thrombolysis bleeding risk, expanded submassive PE intervention criteria',
  },

  // ──────────────────────────────────────────────────────────
  // UROLOGY
  // ──────────────────────────────────────────────────────────

  {
    name: 'Benign Prostatic Hyperplasia Treatment (Minimally Invasive)',
    synonyms: ['BPH treatment', 'UroLift', 'Rezum', 'Aquablation', 'TURP', 'prostate artery embolization', 'iTind', 'prostatic urethral lift'],
    cpt_codes: ['52441', '52442', '53854', '0421T', '55880'],
    drg_codes: ['665', '666', '667'],
    device_category: 'urology',
    us_annual_procedures: 250000,
    us_procedure_growth_rate: 8.0,
    procedure_setting: ['hospital_outpatient', 'asc', 'office'],
    eligible_sites: { hospitals: 2000, ascs: 1500, clinics: 3000 },
    performing_specialty: ['Urology'],
    adoption_barrier: 'low',
    procedure_source: 'Teleflex/BSC investor data 2024; AUA BPH Guidelines',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 4500,
      medicare_physician_rate: 600,
      private_payer_coverage: 'UroLift and Rezum broadly covered by commercial payers. Aquablation coverage growing. Office-based UroLift reimbursement established.',
    },
    major_device_competitors: [
      'UroLift (Teleflex) — prostatic urethral lift',
      'Rezum (Boston Scientific) — steam/water vapor thermal therapy',
      'AquaBeam/Aquablation (PROCEPT BioRobotics) — robotic waterjet',
      'iTind (Olympus) — temporary implant',
      'Greenlight XPS (Boston Scientific) — laser vaporization',
    ],
    market_leader: 'Teleflex (UroLift) for MIST; Boston Scientific for surgical',
    market_leader_share_pct: 30,
    current_standard_of_care: 'Medical therapy (alpha-blockers, 5-ARIs) first line. TURP declining. Minimally invasive surgical therapies (MIST) — UroLift, Rezum — growing rapidly. Aquablation for larger prostates.',
    cagr_5yr: 8.0,
    growth_driver: 'MIST adoption over TURP, office-based procedures, Aquablation for large prostates, aging male population, sexual function preservation preference',
  },

  {
    name: 'Extracorporeal Shockwave Lithotripsy',
    synonyms: ['ESWL', 'lithotripsy', 'shockwave lithotripsy', 'kidney stone treatment', 'SWL', 'extracorporeal lithotripsy'],
    cpt_codes: ['50590'],
    drg_codes: ['693', '694'],
    device_category: 'urology',
    us_annual_procedures: 70000,
    us_procedure_growth_rate: -3.0,
    procedure_setting: ['hospital_outpatient', 'asc'],
    eligible_sites: { hospitals: 1500, ascs: 500 },
    performing_specialty: ['Urology'],
    adoption_barrier: 'low',
    procedure_source: 'AUA Kidney Stone Guidelines 2024; CMS claims data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 3500,
      medicare_physician_rate: 500,
      private_payer_coverage: 'Universal coverage for symptomatic renal stones. Declining use as ureteroscopy (URS) has gained preference for many stone types/locations.',
    },
    major_device_competitors: [
      'Dornier (lithotripsy systems)',
      'Storz Medical (lithotripters)',
      'Richard Wolf (lithotripsy)',
      'Siemens Healthineers',
      'Boston Scientific (stone management devices)',
    ],
    market_leader: 'Dornier',
    market_leader_share_pct: 35,
    current_standard_of_care: 'ESWL declining as ureteroscopy (URS) with laser lithotripsy gains share. ESWL remains option for smaller (<2cm) renal stones. URS now ~300K procedures/yr in US.',
    cagr_5yr: -3.0,
    growth_driver: 'Declining procedure — being replaced by ureteroscopy with holmium/thulium laser. Remaining niche for small proximal ureteral and renal stones in selected patients',
  },

  {
    name: 'Robotic Cystectomy',
    synonyms: ['robotic radical cystectomy', 'RARC', 'robot-assisted cystectomy', 'bladder removal robotic', 'da Vinci cystectomy'],
    cpt_codes: ['51595', '51596', '51597'],
    drg_codes: ['653', '654', '655'],
    device_category: 'urology',
    us_annual_procedures: 18000,
    us_procedure_growth_rate: 5.0,
    procedure_setting: ['hospital_inpatient'],
    eligible_sites: { hospitals: 800 },
    performing_specialty: ['Urology', 'Urologic Oncology'],
    adoption_barrier: 'moderate',
    procedure_source: 'NSQIP Surgical Database 2024; Intuitive Surgical procedure data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 18000,
      medicare_physician_rate: 2200,
      private_payer_coverage: 'Universal coverage. Robotic approach not separately reimbursed but accepted as standard surgical approach.',
    },
    major_device_competitors: [
      'da Vinci Xi (Intuitive Surgical) — dominant',
      'Hugo RAS (Medtronic) — emerging',
      'Versius (CMR Surgical) — EU',
    ],
    market_leader: 'Intuitive Surgical',
    market_leader_share_pct: 85,
    current_standard_of_care: 'Radical cystectomy with urinary diversion for muscle-invasive bladder cancer. Robotic approach now >60% of cases at academic centers. Intracorporeal urinary diversion gaining adoption.',
    cagr_5yr: 5.0,
    growth_driver: 'Intracorporeal urinary diversion adoption, ERAS protocols reducing LOS, competitive robotic platforms, bladder cancer incidence stable',
  },

  // ──────────────────────────────────────────────────────────
  // ENT
  // ──────────────────────────────────────────────────────────

  {
    name: 'Cochlear Implant',
    synonyms: ['CI', 'cochlear implantation', 'cochlear implant surgery', 'hearing implant', 'Cochlear Nucleus', 'AB implant'],
    cpt_codes: ['69930'],
    drg_codes: ['129', '130'],
    device_category: 'ent',
    us_annual_procedures: 15000,
    us_procedure_growth_rate: 8.0,
    procedure_setting: ['hospital_outpatient', 'hospital_inpatient'],
    eligible_sites: { hospitals: 400 },
    performing_specialty: ['Otolaryngology', 'Neurotology'],
    adoption_barrier: 'moderate',
    procedure_source: 'Cochlear Limited/MED-EL/AB investor data 2024; AAO-HNS data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 30000,
      medicare_physician_rate: 2000,
      private_payer_coverage: 'Covered for severe-to-profound sensorineural hearing loss. Bilateral implantation coverage improving. Expanded audiometric criteria (2023 FDA guidance) driving growth.',
    },
    major_device_competitors: [
      'Nucleus 8 (Cochlear Limited) — market leader',
      'HiRes Ultra 3D (Advanced Bionics/Sonova)',
      'SYNCHRONY 2 (MED-EL)',
    ],
    market_leader: 'Cochlear Limited',
    market_leader_share_pct: 60,
    current_standard_of_care: 'Cochlear implant for severe-to-profound SNHL. FDA expanded criteria in 2023 (single-sided deafness, expanded audiometric criteria). Bilateral CI standard for children.',
    cagr_5yr: 8.0,
    growth_driver: 'Expanded FDA criteria (2023), single-sided deafness indication, adult bilateral implantation, aging population hearing loss, massive underutilization (only ~5% of eligible adults implanted)',
  },

  {
    name: 'Balloon Sinuplasty',
    synonyms: ['BSP', 'balloon sinus dilation', 'balloon sinuplasty', 'sinus balloon', 'Relieva', 'XprESS'],
    cpt_codes: ['31295', '31296', '31297', '31298'],
    drg_codes: [],
    device_category: 'ent',
    us_annual_procedures: 150000,
    us_procedure_growth_rate: 7.0,
    procedure_setting: ['office', 'asc', 'hospital_outpatient'],
    eligible_sites: { hospitals: 1000, ascs: 1500, clinics: 3000 },
    performing_specialty: ['Otolaryngology'],
    adoption_barrier: 'low',
    procedure_source: 'Stryker/J&J ENT investor data 2024; AAO-HNS guidelines',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_facility_rate: 2500,
      medicare_physician_rate: 400,
      private_payer_coverage: 'Broadly covered for chronic rhinosinusitis failing medical therapy. In-office balloon sinuplasty reimbursed. Some payers require CT scan confirmation and medical therapy failure.',
    },
    major_device_competitors: [
      'NuVent (Stryker) — balloon dilation',
      'Relieva (Acclarent/J&J) — pioneer',
      'XprESS (Entellus Medical/Stryker)',
      'SINUVA (Intersect ENT/Medtronic) — steroid-eluting implant',
      'Propel (Intersect ENT/Medtronic) — steroid-eluting stent',
    ],
    market_leader: 'Stryker (NuVent + XprESS)',
    market_leader_share_pct: 45,
    current_standard_of_care: 'In-office or ASC balloon sinus dilation for chronic sinusitis. Less invasive than functional endoscopic sinus surgery (FESS). Often combined with steroid-eluting implants.',
    cagr_5yr: 7.0,
    growth_driver: 'In-office procedure shift, steroid-eluting implant combination, patient preference for minimally invasive approach, ENT practice economics',
  },

  // ──────────────────────────────────────────────────────────
  // DERMATOLOGY
  // ──────────────────────────────────────────────────────────

  {
    name: 'Mohs Surgery for Skin Cancer',
    synonyms: ['Mohs micrographic surgery', 'Mohs surgery', 'MMS', 'skin cancer excision', 'Mohs dermatology'],
    cpt_codes: ['17311', '17312', '17313', '17314', '17315'],
    drg_codes: [],
    device_category: 'dermatology',
    us_annual_procedures: 850000,
    us_procedure_growth_rate: 4.0,
    procedure_setting: ['office'],
    eligible_sites: { hospitals: 0, clinics: 3500 },
    performing_specialty: ['Dermatology', 'Mohs Surgery'],
    adoption_barrier: 'low',
    procedure_source: 'ACMS (American College of Mohs Surgery) 2024; CMS claims data',
    reimbursement: {
      cms_coverage: 'covered',
      medicare_physician_rate: 350,     // per stage (typically 1-3 stages)
      private_payer_coverage: 'Universal coverage for appropriate-use criteria (AUC) indications. Office-based procedure. Reimbursement per stage plus reconstruction/closure codes.',
    },
    major_device_competitors: [
      'Cryostat microtome systems (Leica, Thermo Fisher)',
      'Tissue staining systems (Leica, Sakura)',
      'Electrosurgery units (Ellman/Cynosure, Bovie)',
      'Digital pathology for Mohs (emerging)',
    ],
    market_leader: 'Leica Biosystems (cryostat systems)',
    market_leader_share_pct: 50,
    current_standard_of_care: 'Gold standard for high-risk BCC and SCC on face/cosmetically sensitive areas. Same-day margin analysis with >99% cure rate. Expanding to melanoma in situ.',
    cagr_5yr: 4.0,
    growth_driver: 'Rising skin cancer incidence, aging population, expanding AUC indications, digital pathology integration for frozen section reading',
  },

  {
    name: 'Laser Treatment for Vascular/Pigmented Lesions',
    synonyms: ['laser dermatology', 'pulsed dye laser', 'PDL', 'IPL', 'Nd:YAG laser', 'alexandrite laser', 'laser skin treatment', 'vascular laser'],
    cpt_codes: ['17110', '17111', '96920', '96921', '96922'],
    drg_codes: [],
    device_category: 'dermatology',
    us_annual_procedures: 600000,
    us_procedure_growth_rate: 5.0,
    procedure_setting: ['office'],
    eligible_sites: { hospitals: 0, clinics: 5000 },
    performing_specialty: ['Dermatology', 'Plastic Surgery'],
    adoption_barrier: 'low',
    procedure_source: 'Cynosure/Candela investor data 2024; ASLMS data',
    reimbursement: {
      cms_coverage: 'partial',
      medicare_physician_rate: 200,
      private_payer_coverage: 'Medical indications covered (port wine stains, hemangiomas, rosacea, surgical scars). Cosmetic uses (age spots, tattoo removal, facial rejuvenation) not covered — patient self-pay.',
    },
    major_device_competitors: [
      'Vbeam (Candela/Syneron) — pulsed dye laser',
      'Excel V+ (Cutera) — dual wavelength',
      'PicoSure/PicoWay (Cynosure) — picosecond',
      'Icon/Stellar M22 (Cynosure) — IPL platform',
      'Nordlys (Candela) — IPL/laser combination',
    ],
    market_leader: 'Candela (Vbeam + Nordlys)',
    market_leader_share_pct: 30,
    current_standard_of_care: 'Pulsed dye laser (595nm) gold standard for vascular lesions. Q-switched/picosecond lasers for pigmented lesions and tattoo removal. IPL for diffuse photodamage.',
    cagr_5yr: 5.0,
    growth_driver: 'Growing medical aesthetics market, picosecond technology for faster clearance, combination treatments, telemedicine consults driving referrals',
  },

];

// ────────────────────────────────────────────────────────────
// Helper functions
// ────────────────────────────────────────────────────────────

export function findProcedureByName(name: string): ProcedureData | undefined {
  const q = name.toLowerCase().trim();
  return PROCEDURE_DATA.find(p =>
    p.name.toLowerCase() === q ||
    p.synonyms.some(s => s.toLowerCase() === q || s.toLowerCase().includes(q) || q.includes(s.toLowerCase()))
  );
}

export function getProcedureSuggestions(query: string): ProcedureData[] {
  if (!query || query.length < 2) return PROCEDURE_DATA.slice(0, 10);
  const q = query.toLowerCase();
  return PROCEDURE_DATA.filter(p =>
    p.name.toLowerCase().includes(q) ||
    p.synonyms.some(s => s.toLowerCase().includes(q)) ||
    p.device_category.includes(q)
  ).slice(0, 10);
}

export function getProceduresByCategory(category: ProcedureData['device_category']): ProcedureData[] {
  return PROCEDURE_DATA.filter(p => p.device_category === category);
}
